Tuesday 21 July Poster Exhibition

Size: px
Start display at page:

Download "Tuesday 21 July Poster Exhibition"

Transcription

1 Venue: Hall B on the West Exhibition Level Presentation: Tuesday 21 July, 12:30-14:30 The Poster Exhibition is open from Monday 20 - Wednesday 22 July from 10:00 to 18:30. Posters will be displayed for the duration of the conference (Monday to Wednesday). Authors will stand by their posters between 12:30 and 14:30 to answer questions and provide further information on their study results on their presentation day. Late breaker posters are also displayed for the duration of the conference in the Poster Exhibition area. Track A > PEA049-A050 Viral origins and evolution TUPEA049 TUPEA050 TUPEA051 TUPEA052 TUPEA053 TUPEA054 TUPEA055 TUPEA056 Basic Science Phylogenetic estimation of the temporal spread of hepatitis C genotype 1a in North America J. Joy, R. McCloskey, T. Nguyen, R. Liang, Y. Khudyakov, A. Olmstead, M. Krajden, J. Ward, P.R. Harrigan, J. Montaner, A. Poon Origin and evolutionary history of HIV-2 in Cuba L.Y. Machado, O. Martínez, H.M. Díaz, M. Blanco, E. Noa, D. Romay, M. Dubed Cuba PEA051-A062 Viral diversity, phylogenetics, phylodynamics Molecular epidemiology of clinical HIV-1 pol sequences isolated between January 2009 and July 2013 in Cuba V. Kouri Cardella, L. Pérez, Y. Aleman, J. Perez, C. Fonseca, C. Correa, C. Aragonés, L.M. Ortega, J. Campos, Y. Schrooten, L. Vinken, Y. Soto, C.M. Limia, A.-M. Vandamme, K. Van Laethem Cuba The Local Dissemination Impact of the HIV-1 env LDI tripeptide a4ß7 binding motif S. Helmold Hait, E. Stankiewicz Machado, E. Augusta Soares, E. Sprinz, M. Alves Soares Brazil Evolution of the HIV-1 envelope gene during suppressive cart J. Bader, M. Däumer, A. Thielen, J. Böni, M. Gorgievski-Hrisoho, T. Klimkait, The Swiss HIV Cohort Study Switzerland Multiplexed highly-accurate nextgeneration sequencing of mixtures of fulllength HIV genome variants D. Dilernia, J. Ting-Chien, D. Monaco, M. Brown, Z. Ende, M. Deymier, L. Yue, E. Paxinos, S. Allen, A. Tirado-Ramos, E. Hunter HIV-1 circular recombinant CRF02-AG: rapid spread in Russia and neighboring countries F. Moskaleychik, V. Laga, E. Delgado, Y. Vega, A. Fernandez-Garcia, L. Perez-Alvarez, G. Kornilaeva, A. Pronin, Y. Zhernov, A. Tatarintsev, A. Turgiev, M. Thomson, M. Bobkova, E. Karamov Russian Federation A new framework for reconstructing epidemic dynamics from virus sequences: model validation and application to the HIV CRF07-BC epidemic in China A. Poon TUPEA057 TUPEA058 TUPEA059 TUPEA060 TUPEA061 TUPEA062 TUPEA063 Prevalence, evolutionary dynamics and transmission pattern of HCV, HIV-1 and HPgV among injecting drug users K.T. Ng, Y. Takebe, Y.M. Lee, A. Wahab, W.Z. Chow, H.A. Abed Al-Darraji, L.Y. Ong, A. Kamarulzaman, K.K. Tee Malaysia Identification and genetic characterisation of a novel HIV-1 circulating recombinant lineage (CRF74_01B) among people who inject drugs in Malaysia H.T. Cheong, W.Z. Chow, Y. Takebe, J.B. Chook, K.G. Chan, H.A. Al-Darraji, C. Koh, A. Kamarulzaman, K.K. Tee Malaysia Kive: a framework for version control of bioinformatic pipelines and data, and its application to HIV resistance genotyping R. Liang, E. Martin, R. McCloskey, D. Kirkby, J. Nakagawa, T. Nguyen, P.R. Harrigan, A. Poon Newly diagnosed HIV-1 infections in frequently group in clusters of subtype B and non-subtype B genetic forms E. Delgado, J. Martínez, M.T. Cuevas, A. Fernández-García, Y. Vega, V. Montero, C. Carrera, M. Sánchez, E. García-Bodas, L. Pérez-Álvarez, M.M. Thomson, Spanish Group for the Study of HIV-1 Antiretroviral Drug Resistance and Tropism Prevalence of defective HIV-1 genome in HIV-infected patients on long-term cart and correlation with characteristics of patients C. Psomas, B. Montès, S. Eymard-Duvernay, V. Le Moing, E. Delaporte, J. Reynes, A. Makinson France Full-length ultra-deep sequencing of HIV- 1 transmission partners reveals the impact of intra-host evolution on immune control J. Brener, R. Batorsky, A. Gall, P. Kellam, T. Allen, P. Goulder, P.C. Matthews PEA063-A065 Viral fitness TUPEA064 TUPEA065 Consequences of HLA-B*13-associated escape mutations on HIV-1 replication and Nef protein function A. Shahid, X.T. Kuang, G. Anmole, A. Olvera, L. Cotton, C. Brander, M.A. Brockman, Z.L. Brumme Drug susceptibility and viral fitness of integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations in combination K. Andreatta, M. Miller, K. White SIV CTL escape mutations resulting in loss of viral fitness can be maintained after transmission into MHC-I-mismatched hosts T. Nomura, S. Seki, M. Nishizawa, S. Harada, K. Yoshimura, T. Matano Japan PEA066-A068 Antiretroviral resistance mechanisms 1 / 17

2 TUPEA066 TUPEA067 TUPEA068 TUPEA069 Transmission dynamics of local networks of transmitted resistance to NNRTIs suggest an increasing incidence over time in Greece: the added value of molecular epidemiology to public health D. Paraskevis, A. Zavitsanou, E. Magiorkinis, P. Gargalianos, G. Xylomenos, M. Lazanas, M. Chini, A. Skoutelis, V. Papastamopoulos, A. Antoniadou, A. Papadopoulos, M. Psichogiou, G. Daikos, G. Chrysos, V. Paparizos, S. Kourkounti, H. Sambatakou, N. Sipsas, G. Koratzanis, P. Panagopoulos, Ε. Maltezos, S. Drimis, A. Hatzakis Greece HIV resistance pathways support the use of lamivudine (3TC) and dolutegravir (DTG) in combination T. Mesplède, D. Singhroy, B. Spira, M. Wainberg Evolution of HIV-1 integrase following selection of R263K with further dolutegravir treatment: a case report from the P1093 study C. Vavro, P. Palumbo, A. Wiznia, C. Alvero, B. Graham, T. Fenton, R. Hazra, E. Townley, A. Buchanan, J. Horton, R. Viani, P1093 Study Group PEA069-A073 Host genetics of HIV susceptibility and disease progression TUPEA070 TUPEA071 TUPEA072 TUPEA073 PEA074 TUPEA074 Degradation of HIV-1 Nef by ubiquitin (Ub) specific protease 15 (USP15) I.-W. Park, D. Pyeon Independent association of host immunogenetic factors with vertical HIV transmission J. Mania-Pramanik, S. Ahir-Bist, V. Chavan, S. Kerkar, P. Samant-Mavani, R. Nanavati, P. Mehta India Expression analysis of a4 integrin and related genetic polymorphisms in HIV acquisition and disease progression of infected individuals L.R. Goes, A.L. Moraes Giannini, S. Helmold Hait, E. Stankiewicz Machado, D. Alves Costa, E. Georges Kallás, L.C. Santos Thuler, A.F. Andrade dos Santos, J. Arthos, M. Alves Soares Brazil Human leukocyte antigen (HLA) typing and novel allele description by next generation sequencing in HIV-1-infected individuals from Southern Brazil I. Prellwitz, B. Alves, E. Sprinz, H.N. Seuanez, M. Soares, E. Soares Brazil Absence of an association between mannose binding lectin deficiency and HIV-1 disease progression in an adult population in Zimbabwe R.B.L. Zinyama-Gutsire, C. Chasela, P. Per Kallestrup, S. Rusakaniko, M. Christiansen, B. Ngara, E. Gomo, H. Ullum, C. Erikstrup, H.O. Madsen, B. Stray-Pedersen, P. Garred, T. Mduluza Systems biology approaches to HIV infection Global mapping of HIV-1 and host-cells molecular interactions A. Deshiere, I. Martinez-Ferrando, C. Joly- Beauparlant, Y. Breton, M. Ouellet, C. Mohien, F. Raymond, L. Robitaille, J. Corbeil, D.R. Graham, M.J. Tremblay, Laboratory of Human Immuno-Retrovirology PEA075-A082 Preclinical drug development TUPEA075 TUPEA076 TUPEA077 TUPEA078 TUPEA079 TUPEA080 TUPEA081 TUPEA082 TUPEA083 TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human PBMCs R.A. Bam, S.R. Yant, A. Irrinki, J. Hesselgesser, C.R. Frey, T. Cihlar A novel acylguanidine-based inhibitor of HIV-1 egress P. Mwimanzi, I. Tietjen, A. Shahid, S.C. Miller, D. Fedida, Z. Brumme, M. Brockman Novel CD4-mimetic small molecules show enhancement of the neutralization activity of anti-cryptic V3 neutralizing antibody, KD-247 S. Harada, Y. Irahara, H. Tamamura, T. Matano, S. Matsushita, K. Yoshimura Japan BMS : characterization of a 2ndgeneration HIV-1 maturation inhibitor B. Nowicka-Sans, T. Protack, Z. Lin, Z. Li, S. Zhang, N. Meanwell, M. Cockett, A. Regueiro- Ren, M. Krystal, I. Dicker Small molecule activator of protein phosphatase 1 (SMAPP1) activates latent HIV-1 provirus T. Ammosova, M. Tyagi, S. Iordanskiy, K. Smith, N. Kumari, A. Ilatovskiy, Y. Saygideger- Kont, A. Ivanov, A. Uren, D. Kovalskyy, M. Petukhov, F. Kashanchi, S. Nekhai Discovery and anti-hiv-1 activity of a new class of diheteroarylamide-type anti-hiv- 1 agents acting on HIV-1 alternative splicing P. Cheung, D. Horant, L. Bandy, S. Karagiosov, P.R. Harrigan, B. Chabot, D. Grierson Discovery of novel HIV-1 inhibitors from natural products I. Tietjen, K. Andrae-Marobela, D. Williams, F. Ntie-Kang, P. Mwimanzi, P. Amoa Onguéné, B.M. Abegaz, R. Andersen, D. Fedida, Z.L. Brumme, M.A. Brockman Development of efficient parallel synthesis strategies for the generation of compound libraries of anti-hiv agents that alter HIV alternative splicing M. Zamiri, Z.S. Lin, A. Koperniku, B. Chabot, P. Cheung, D. Grierson PEA083-A084 Preclinical microbicide development TUPEA084 TUPEA085 Antiviral activity of 5-Hydroxytyrosol, a microbicidal candidate against HIV-1 transmission L.M. Bedoya, M. Beltrán, P. Obregón, E. Gómez-Acebo, D. Auñon, L. Capa, J. Alcami Protection from HIV-1 infection by S-layer mediated display of anti-hiv proteins on Caulobacter crescentus C. Farr Zuend, J.F. Nomellini, J. Smit, M.S. Horwitz PEA085-A095 Targeting HIV persistence during ART (cure strategies) MG1 and VSV?51 viruses target and kill latently HIV-infected myeloid cells N. Ranganath, S. Côté, T. Sandstrom, J. Angel 2 / 17

3 TUPEA086 TUPEA087 TUPEA088 TUPEA089 TUPEA090 TUPEA091 TUPEA092 TUPEA093 TUPEA094 TUPEA095 Risk of virologic rebound in HIV-infected patients on HAART with very low-level viraemia S.-Y. Chan, T.H.-C. Tang, W. Lam, T.-S. Kwong, M.-Y. Chu, Y.-T. Chan, M.-P. Lee, P.C.- K. Li, T.-C. Wu Hong Kong, SAR of China Minimal HIV-1 Gag epitope presentation in a T cell line during reactivation X.T. Kuang, G. Anmole, P. Mwimanzi, M.A. Brockman Vorinostat, panobinostat and romidepsin nonselectively activate transcription from quiescent HIV-1 proviruses in HIVinfected individuals on long-term suppressive antiretroviral therapy K. Barton, T.A. Rasmussen, M. Tolstrup, W. Shao, B. Hiener, R. Olesen, A. Winckelmann, A. Solomon, L. Østergaard, S.R. Lewin, O.S. Søgaard, S. Palmer Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle efficiently limits viral reactivation and halts viral replication M. Nijhuis, D. de Jong, F. Wolters, E. Wiertz, R.J. Lebbink Netherlands Universal Tre-recombinase (utre) specifically targets the majority of primary HIV-1 isolates I. Hauber, J. Karpinski, C. Schäfer, J. Chemnitz, H. Hofmann-Sieber, J. van Lunzen, F. Buchholz, J. Hauber Germany Polyvalent immune responses correlate with lower number of HIV-infected CD4 T cells in chronically infected subjects treated with autologous RNA pulsed DC therapy I. Tcherepanova, J. Krisko, J. Harris, A. Gamble, W. Lewis, M. DeBenedette, C. Nicolette Latency reversal Agent (LRA) romidepsin reactivates latent virus in two rhesus macaque (RM) models of controlled SIV infection in the absence of antiretroviral therapy (ART) B. Policicchio, E. Brocca-Cofano, C. Xu, D. Ma, T. He, H. Li, G. Haret-Richter, T. Dunsmore, G. Shaw, R. Ribeiro, I. Pandrea, C. Apetrei Robust HIV-specific T cells in posttreatment controllers from the VISCONTI cohort A. Samri, V. Avettand-Fenoel, L. Hocqueloux, C. Bacchus-Souffan, A. Cheret, A. Emarre, B. Descours, A. Saez-Cirion, C. Rouzioux, B. Autran, VISCONTI Study Group France Nef inhibition for enhanced NK cell killing of cells expressing reactivated HIV-1 E. Scully, A. Lockhart, W. Garcia Beltran, A. Bodair, M.-C. Rouyez, S. Benichou, D. Kuritzkes, M. Altfeld Emergence of infectious treatmentresistant HIV after provirus-directed endonuclease therapy H.S. De Silva Feelixge, M. Aubert, D. Stone, K.R. Jerome PEA096-A099 Novel approaches in Immunotherapeutics (including bnabs and anti-inflammatory mediators) TUPEA096 TUPEA097 TUPEA098 TUPEA099 Track B > TUPEB216 TUPEB217 TUPEB218 TUPEB219 TUPEB220 TUPEB221 Selection and evaluation of specific single chain antibodies against gp41 of HIV F. Nejatollahi, H. Joulaei, R. Robati Iran, Islamic Republic of Antibody-dependent cellular cytotoxicity against cells latently infected with HIV W.S. Lee, M. Lichtfuss, M.S. Parsons, S. Kent Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitope K. Tanaka, T. Kuwata, Y. Maruta, K. Ramirez, M. Alam, Y. Egami, Y. Kawanami, S. Matsushita Japan A novel TLR-9 agonist (MGN1703) activates NK-cells and enhances NK-cell mediated viral killing of HIV-1 infected CD4+ T cells ex vivo R. Offersen, M. Tolstrup, S.K. Nissen, T. Rasmussen, L. Østergaard, P.W. Denton, O.S. Søgaard Denmark Clinical Science PEB216-B222 HIV testing (including new algorithms, rapid/point of care testing and strategies) What individual and contextual factors are associated with rapid HIV test utilization in the U.S.? R. Serrano, M. Philyaw, D. Lodin High acceptability of rapid HIV test in Argentina: experience during a seroprevalence study in vulnerable groups A. Duran, D. Rossi, R. Marone, G. Orellano, M. Romero, C. Petracca, E. Benedetti, M.M. Avila, H. Salomón, M.A. Pando Argentina Novel diagnostic peptide epitope biomarkers for detection and identification of recent and longstanding HIV infection using the Europium Nanoparticle Immuno Assay (ENIA) M.K. Haleyur Giri Setty, Z. Panhe, J. Liu, B. Du, S.M. Keating, M.P. Busch, C. Pilcher, M. Cohen, B.F. Haynes, M. Vermeulen, I.K. Hewlett Performance of the determine HIV 1/2 Ag/Ab combo rapid test for detecting acute HIV infection: a systematic review and Bayesian meta-analysis M. Smallwood, R. Vijh, B. Nauche, B. Lebouché, L. Joseph, N. Pant Pai Roll-out of a national early infant diagnosis program in Papua New Guinea, I. Silas, P. Desai, E. Lavu, M. Kiromat Papua New Guinea Performance of the Trinity Biotech Uni- Gold HIV 1/2 rapid test as a first-line screening assay for gay and bisexual men compared with 4th generation immunoassays P. Keen, D.P. Conway, P. Cunningham, A. Mcnulty, D.L. Couldwell, S.C. Davies, D.E. Smith, J. Gray, M. Holt, C. O'connor, R. Finlayson, J. Mcallister, B. Hughes, C. Carmody, R. Varma, D. Smith, P. Read, D. Callander, R. Pickles, R. Guy 3 / 17

4 TUPEB222 PEB223 TUPEB223 TUPEB224 Evaluation of SD bioline HIV Ag/Ab assay for detection acute HIV infection (AHI) A. Drake, D. Matemo, J. Kinuthia, S. McClelland, J. Klausner, G. John-Stewart Kenya CD4 measurement (including point of care diagnostics) A meta-analysis of the performance of the PimaTM CD4 for point of care testing L. Scott, J. Campbell, L. Kestens, L. Vojnov, T. Peter, W. Stevens PEB224-B226 Viral load measurement (including point of care diagnostics) TUPEB225 TUPEB226 TUPEB227 Assessment of new technology for the scale up of HIV viral load monitoring in S. Carmona, Z. Mahlumba, B. Seiverth, E.G. Marins, B.R. Cobb, C. Simon, W. Stevens Alere TM q HIV-1/2 POC assay on plasma rather than whole blood, yields adequate viral load results L. Hans, N. Ndongwane, A. Mayne, L. Gonzales, S. Carmona Accuracy of HIV viral load testing with dried plasma spot (DPS) samples for identifying virological failures: primary data from 11 field studies L. Vojnov, C. Zeh, M. Prescott, C. Boeke, T. Peter, C. Yang, DPS for VL Diagnostics Investigation Consortium Tanzania, United Republic of PEB227-B234 Drug resistance testing TUPEB228 TUPEB229 TUPEB230 TUPEB231 Alarming levels of drug resistance in HIV- 1-infected patients failing treatment in Cuba L. Pérez, Y. Alemán, C. Correa, J. Perez, C. Fonseca, C. Aragonés, J. Campos, D. Álvarez, Y. Schrooten, L. Vinken, D. Pérez, A. Álvarez, Y. Soto, C. Limia, A.-M. Vandamme, K. Van Laethem, V. Kourí Cuba Prevalence of primary HIV drug resistance by short reverse transcriptase genotypic resistance assay in Thailand S. Kiertiburanakul, S. Pinsai, W. Chantratita, E. Pasomsub, M. Leechawengwongs, N. Siriyakorn, S. Sungkanuparph Thailand Establishment of an Illumina MiSeq-based HIV drug resistance testing platform H. Ji, T. Taylor, E. Enns, M.-K. Gauthier, R. Capina, B. Liang, G. Van Domselaar, P. Sandstrom, J. Brooks Validating the World Health Organization HIV drug resistance early warning indicators L. Lourenco, H. Ma, R. Harrigan, P. Sereda, J. Montaner, V. Lima High prevalence of NNRTI HIV drug resistance in children under 18 months of age recently diagnosed with HIV: results from a national survey in S. Carmona, K. Steegen, G. Hunt, L. Morris, I. Sanne, W. Stevens, G. Sherman TUPEB232 TUPEB233 TUPEB234 TUPEB235 Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance observed in a national survey in K. Steegen, S. Carmona, M. Bronze, M.A. Papathanasopoulos, G. Van Zyl, D. Goedhals, W. Macleod, I. Sanne, W.S. Stevens Prevalence of HIV-1 cross-resistance against dolutegravir and elvitegravir in raltegravir-experienced patients in Germany over the past five years F. Wiesmann, T. Goodarzi, P. Braun, H. Knechten Germany High frequency of genotypic resistance in HIV-1-infected patients on highiy active antiretroviral therapy with persistent low viremia D. Pellegrino, J. Souza Cavalcanti, J.L. Ferreira, L.F. Brígido Macedo Brazil PEB235-B237 Diagnostics of co-infections (including syphilis, TB, Cryptococcus, hepatitis B, C and other) TUPEB236 TUPEB237 TUPEB238 Global performance of GeneXpert (Xpert MTB/RIF, Cepheid) using standardized verification and external quality assessment material L. Scott, V. Magida, A. David, V. Deyde, A. Adelekan, C. Gilpin, R. Coombs, W. Stevens, Xpert MTB/RIF EQA consortium Routine eye screening by an ophthalmologist is clinically useful for HIV-1-infected patients with CD4 count less than 200 /µl T. Nishijima, S. Yashiro, K. Teruya, Y. Kikuchi, N. Katai, H. Gatanaga, S. Oka Japan Association between transient elastography (TE) scores and AST to platelet ratio index (APRI) among HIV/HCV co-infected patients M. Harris, M. Hull, A. Moghadam, G. Larsen, W. Zhang, B. Ganase, T. Kozai, B. Yip, R. Hogg, J. Montaner PEB238-B255 Hepatitis C TUPEB239 TUPEB240 TUPEB241 Decreasing prevalence of HCV-HIV coinfection ( ) in Madrid, A. Díaz-De Santiago, S. Serrano, B. Sastre, C. Gómez-Ayerbe, S. Bañón-Escandell, E. Loza, C. Quereda, A. Moreno, J.L. Casado, M.J. Pérez Elíaz, S. Moreno No difference in safety profiles comparing 12- and 24-week HCV treatment durations in HCV genotype 1 and HIV-1 co-infected patients: results from TURQUOISE-I J.J. Eron, J. Slim, R. Elion, R. D'Amico, R. Trinh, Y.B. Hu, M. Co, D. Wyles Low incidence of reinfection with hepatitis C virus after successful treatment in Montreal N. Machouf, B. Trottier, C. Galanakis, E. Huchet, M. Poliquin, S. Vézina, S. Lavoie, D. Longpré, D. Legault, R. Thomas Fibrosis regression is possible after a successful treatment of hepatitis C even with cirrhosis B. Trottier, E. Huchet, M. Poliquin, M.-M. Bellon, S. Vézina, C. Galanakis, D. Longpré, S. Lavoie, R. Thomas, N. Machouf 4 / 17

5 TUPEB242 TUPEB243 TUPEB244 TUPEB245 TUPEB246 TUPEB247 TUPEB248 TUPEB249 TUPEB250 TUPEB251 HCV continuum of care among sex workers living with and affected by HIV, : need for increased access to HCV services alongside HIV prevention efforts M.E. Socías, K. Shannon, J. Montaner, S. Guillemi, S. Dobrer, P. Nguyen, S. Goldenberg, K. Deering Pro-inflammatory gene expression remains altered after successful HCV treatment P. Waldron, M. Holodniy Genetic variation in IL-6 and HLA-DBQ1 genes are associated with spontaneous clearance of hepatitis C virus infection P. Waldron, I. Belitskaya-Levy, A. Chary, L.C. Lazzeroni, A. Monto, J. Ryan, M. Holodniy Favourable IFNL3 genotypes and liver fibrosis in HIV-hepatitis C (HCV) coinfected individuals from the Canadian Coinfection Cohort N. Moqueet, R. Platt, M. Hull, C. Cooper, S. Walmsley, J. Gill, M. Klein, Canadian Coinfection Cohort The risk of cardiovascular disease and death over 10 years in HIV/HCV coinfected patients with and without steatosis C. Down, N. Mehta, K. Marks Implications of baseline HCV RNA level and intrapatient viral load variability on OBV/PTV/r + DSV 12-week treatment outcomes R. Brown, M. Puoti, C. Cooper, D. Wyles, T. Sepe, R. Nahass, M. King, E. Coakley, B. McGovern, J. Feld, R. Trinh National trend and characteristics of acute hepatitis C among HIV-infected individuals: a matched case-control study? Taiwan, June December 2014 Y.-C. Lo Taiwan, China High efficacy and low relapse rates observed with 8 or 12 weeks of LDV/SOF STR in GT1 HCV infected treatment-naïve, non-cirrhotic patients with pretreatment HCV RNA < 6 million IU/mL D.L. Wyles, P.Y. Kwo, S. Zeuzem, G. Foster, P.E. Sax, T. McLean, S. Seyedkazemi, C. Avila, B. Kreter, P.S. Pang, K. Kowdley The impact of serosorting on hepatitis C and HIV co-infection amongst men who have sex with men: a modelling analysis L. MacGregor, N. Martin, A. Ganesh, F. Hickson, P. Weatherburn, P. Vickerman Pending availability and affordability of new HCV regimens in resource-limited settings, should HIV-HCV co-infected patients start receive peg-interferon and ribavirin which just started to be affordable? G. Jourdain, J. Figoni, K. Thetket, P. Leenasirimakul, V. Klinbuayaem, S. Khusuwan, C. Bowonwatanuwong, S. Chalermpantmetagul, T.R. Cressey, L. Decker, N. Durier, N. Salvadori, N. Ngo-Giang-Huong, PHPT HIV-HCV Treatment Group Thailand TUPEB252 TUPEB253 TUPEB254 TUPEB255 TUPEB256 Prevalence of HIV, HBV and HCV infections in M. Manak, O. Njoku, A. Shutt, J. Malia, M. Milazzo, A. Suleiman, R. Nelson, O. Ayemoba, R. O'Connell, D. Singer, N. Michael, S. Peel PegIFN-a 2a dose-dependent reduction in HIV-DNA levels during the first 4 weeks of treatment in HIV-1/HCV co-infected patients O.-J. BenMarzouk-Hidalgo, A. Torres-Cornejo, A. Gutierrez-Valencia, R.M. Ruiz-Valderas, P. Viciana, L.F. López-Cortés Global systematic review and metaanalysis of the seroprevalence of HBV and HCV infection in HIV-infected persons P. Easterbrook, L. Platt, E. Gower, H. Razavi, K. Sabin, P. Vickerman WHO Safety of ledipasvir/sofosbuvir with and without ribavirin for the treatment of patients with chronic HCV genotype 1 infection: an analysis of the phase 3 ION trials N. Bräu, S. Alqahtani, N. Afdhal, S. Zeuzem, S. Gordon, A. Mangia, J.C. Yang, X. Ding, P.S. Pang, M.S. Sulkowski PEB256-B260 Other adverse reactions and complications of ART TUPEB257 TUPEB258 TUPEB259 TUPEB260 PEB261 TUPEB261 Adverse drug reactions associated with integrase strand transfer inhibitors (INSTI) in clinical practice: postmarketing experience with raltegravir, elvitegravir-cobicistat and dolutegravir K.J. Lepik, A. Nohpal, B. Yip, K.J. Toy, L. Akagi, J.S.G. Montaner, S. Guillemi, R. Hogg, R. Barrios Physiological concentrations of combination antiretroviral therapy drugs affect mitochondrial DNA (mtdna) quantity and quality in cell culture models S. Saberi, F. Valentino, A. Ziada, A. Hsieh, I. Gadawski, H.C. Côté, the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA) Hearing loss in HIV-infected children in Lilongwe, Malawi S. Hrapcak, H. Kuper, P. Bartlett, A. Devendra, A. Makawa, M. Kim, P. Kazembe, S. Ahmed Serious non-aids events and biomarker changes in HIV-1-infected individuals M. Sunil, N. Utay, R. Arduino, M. Martinez, X. Yu, A. Somasundaram, M. Nigalye, T. Bell Heterogeneity of preferences for antiretroviral drug regimens from the perspective of people living with HIV A. Bayoumi, S. Miles, T. Lin, D. Regier, T. Antoniou, L. Park-Wyllie, C. Strike, J. Hoch, J. Raboud Clinical trials: phase III Safety and efficacy of DTG by age, race and gender: subgroup analysis of 96-week results from treatment-naïve patients in phase III trials [SPRING-2 (ING113086), SINGLE (ING114467) and FLAMINGO (ING114915)] J. Koteff, R. Cuffe, C. Ganier, A. Zolopa, A. Murungi, B. Wynne, M. Aboud 5 / 17

6 PEB262-B263 Timing of therapy initiation TUPEB262 TUPEB263 TUPEB264 Short course versus deferred therapy for the treatment of HIV primary infection: a meta-analysis J. Amin, PHIT, M Study Group CD4 reconstitution is related to CD4 at effective antiretroviral treatment initiation K. Calkins, J. Eron, A. Abraham, K. Buchacz, M. Horberg, J. Tate, S. Napravnik, R. Moore, R. Bosch, B. Lau PEB264-B267 First-line therapy TUPEB265 TUPEB266 TUPEB267 PEB268 TUPEB268 PEB269 TUPEB269 PEB270 Comparison of the effectiveness, tolerability and efficiency (costeffectiveness) of an antiretroviral regimen administered as a single tablet regimen (STR) vs. multiple tablet regimens (MTR) in antiretroviral naïve HIV patients J.M. Gatell, E. de Lazzari, J.M. Molina, S. Gallien, J. Gonzalez-Garcia, A. Imaz, D. Podzamczer, B. Clotet, J.M. Llibre, P. Domingo Treatment outcomes among older HIVinfected adults in Jos, P. Agaba, S. Meloni, H. Sule, R. Ojoh, O. Agbaji, S. Sagay, P. Okonkwo, J. Idoko, P. Kanki ANRS DynaM-O: a 48 weeksprospective study to compare the immuno-virological and clinical responses to HAART between HIV-1 group O and group M-infected patients C. Kouanfack, M. Vray, A. Kfutwah, A. Aghokeng, R. Mougnutou, G. Unal, L. Le Fouler, L. Schaeffer, N. Noumsi, E. Alessandri- Gradt, E. Delaporte, F. Simon, J.-C. Plantier Cameroon CD4 exploders and CD4 peak achievers under ART in a large Italian cohort of HIV-infected subjects M. Lichtner, A. Cozzi Lepri, S. Vita, G. Marchetti, A. Sarracino, A. Gori, C. Mussini, G. Madeddu, A. d'arminio Monforte, Icona Foundation Study Group. Italy Second-line therapy HIV-1+ patients submitted to second line therapy display a comparable immunological biosignature to HIV+ untreated patients while first line therapy partially recovers immune response to a non-infected status M.S. Espindola, L.J.G. Lima, L.S. Soares, M.C. Cacemiro, F.A. Zambuzi, V.S. Brauer, V.R. Bollela, M.S. Gomes, O.A. Martins-Filho, F.G. Frantz Brazil Therapy in highly treatment-experienced persons Regimen switching and virological response in treatment experienced HIV+ patients receiving an integrase inhibitor based regimen: an n cohort study N. De La Mata, D. Cooper, D. Russell, D. Smith, I. Woolley, M. O-Sullivan, S. Wright, M. Law Simplification (with one- or two-agent regimens) and switch studies TUPEB270 TUPEB271 Switch from PI/rtv +2 nucleos(t)ides to RPV+DRV/rtv maintains HIV suppression and is well tolerated F. Maggiolo, D. Valenti, A. Callegaro, E. Di Filippo, G. Gregis, M. Rizzi Italy PEB271-B275 Pharmacology / pharmacokinetics / pharmacogenomics / role of therapeutic drug monitoring TUPEB272 TUPEB273 TUPEB274 TUPEB275 TUPEB276 Renal safety of tenofovir and amphotericin co-administration in treatment of cryptococcal meningitis R. Kiggundu, B.M. Morawski, N.C. Bahr, A. Musubire, D. Williams, K. Huppler Hullsiek, M. Abassi, J.R. Rhein, D.B. Meya, D. R Boulware The pharmacokinetic profiles of dolutegravir in Japanese HIV-1-infected patients M. Takahashi, M. Mizutani, M. Kato, H. Togami, S. Matsumoto, Y. Yokomaku Japan Composite CYP2B6/CYP2A6 genotype and risk for suicidality among HIV-infected individuals randomly assigned to initiate efavirenz-containing regimens in AIDS Clinical Trials Group studies K.R. Mollan, C. Tierney, J.J. Eron, M. Hudgens, R.M. Gulick, R. Haubrich, P.E. Sax, T.B. Campbell, E.S. Daar, K.R. Robertson, Q. Ma, D.W. Haas, AIDS Clinical Trials Group Frequency of tablet remnants of nevirapine extended-release in stools and its impact on virological outcome in HIVinfected Taiwanese: a prospective cohort study S.-Y. Chang, P.-Y. Wu, S.-P. Yang, J.-Y. Zhang, Y.-Z. Luo, W.-C. Liu, Y.-C. Su, M.-J. Wu, S.-Y. Chang, S.-W. Lin, C.-C. Hung Taiwan, China Bioequivalence of two dosage strength fixed-dose combination formulations of F/TAF J. Zack, S. West, M. Rhee, R. Yu, A. Vu, B. Kearney PEB276-B279 Drug interactions TUPEB277 TUPEB278 TUPEB279 Rifabutin for treating tuberculosis in HIVinfected adult patients receiving boosted protease inhibitor containing ART regimen: experiences of neutropenia from an urban clinic T. Mudzviti, T. Shamu, C. Chimbetete, C.C. Maponga, G.D. Morse Zimbabwe HIV-1 attachment inhibitor prodrug BMS : interactions with rifabutin, with or without ritonavir, in healthy subjects R. Adamczyk, A. Griffies, P. Ravindran, C. Smith, J. Anderson, M. Stonier, D.W. Boulton, I. Savant Landry Drug interactions between psychiatric drugs and antiretroviral therapy, adherence and clinical outcomes H. Knobel, E. Molas, A. Retamero, D. Echeverría, A. Guelar, M. Florit, S. Luque Pharmacokinetics and drug interaction potential of multiple-dose tenofovir alafenamide and rilpivirine R. Begley, F. Cheng, E. Lawson, H. Graham, H. Cao, A. Vesterdahl, J. Zack 6 / 17

7 PEB280-B289 Antiretroviral drug resistance TUPEB280 TUPEB281 TUPEB282 TUPEB283 TUPEB284 TUPEB285 TUPEB286 TUPEB287 High rate of transmitted drug resistance in treatment-naïve HIV-infected VCT clients in southern Taiwan, I.T. Chen, P.Y. Chou, Y.H. Chen, H.C. Tsai, S.S.J. Lee Taiwan, China Ten year prevalence of HIV-1 drug resistance mutations in New South Wales, A. Pinto, A. Carrera, H. Salem, K. Thapa, A. Shaik, P. Cunningham, R. Garsia, D. Dwyer, D. Cooper, A. Kelleher Accuracy of WHO guidelines on management of adult patients on ART with unsuppressed viral load: a prospective multicenter study in rural Lesotho N.D. Labhardt, D. Puga, T.I. Lejone, J. Bader, J. Ehmer, I. Ringera, M. Hobbins, B. Cerutti, T. Klimkait Switzerland Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies Q.D. Pham, D.P. Wilson, T.V. Nguyen, N.T. Do, L.X. Truong, L.T. Nguyen, L. Zhang HIV-1 attachment inhibitor prodrug BMS in antiretroviral-experienced subjects: analysis of emergent viral drug resistance through 48 weeks of follow-up M. Lataillade, N. Zhou, S.R. Joshi, S. Lee, D.A. Stock, G.J. Hanna, M. Krystal, for the AI Study Team Analysis of HIV drug resistance in adults receiving early antiretroviral treatment for HIV prevention: results from the HIV prevention trials network (HPTN) 052 trial D. Sabin, S.E. Hudelson, S.S. Ou, S. Hart, C. Wallis, M.G. Morgado, S. Saravanan, S. Tripathy, E. Piwowar-Manning, Y.Q. Chen, M. McCauley, L. Hovind, J. Eron, J. Gallant, T. Gamble, M.C. Hosseinipour, J. Kumwenda, J. Makhema, R. Panchia, J.G. Hakim, V. Akelo, S. Faesen, S. Chariyalertsak, S.V. Godbole, N. Kumarasamy, B. Grinsztejn, J.H. Pilotto, M. Melo, K.H. Mayer, M.S. Cohen, S.H. Eshleman, for the HPTN 052 Study Team Viral blips were infrequent and similar in treatment-naïve adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study D. Porter, R. Kulkarni, W. Garner, M. Miller, K. White Virological response and HIV drug resistance patterns in individuals on first line therapy for at least 4 years without routine viral load measurements: implications for second line regimens F. Lyagoba, A. Kapaata, Z. Cui, P. Kaleebu, C. Mukajjanga, M. Nanfuka, M. Nyonyintono, J. Kim, J. Zhu, P. Munderi, S. Okoboi, J. Birungi, D.M. Moore TUPEB288 TUPEB289 TUPEB290 HIV-1 antiretroviral resistance patterns in patients failing NNRTI-based 1st-line treatment: results from a national survey in K. Steegen, M. Bronze, M.A. Papathanasopoulos, G. Van Zyl, D. Goedhals, W. Macleod, I. Sanne, W.S. Stevens, S. Carmona Prevalence of protease inhibitor and triple-class resistance in patients failing 2nd-line ART: results from a national survey in K. Steegen, M. Bronze, M.A. Papathanasopoulos, G. Van Zyl, D. Goedhals, W. Macleod, I. Sanne, W.S. Stevens, S. Carmona PEB290-B293 Adherence TUPEB291 TUPEB292 TUPEB293 TUPEB294 Influence of the adherence to antiretroviral therapy in the effectiveness of the boosted protease inhibitor dual or monotherapy H. Knobel, A. Retamero, A. Guelar, M. Florit, E. Molas, M. Montero, D. Echeverría, O. Ferrandez, S. Luque Persistent effect of early (M4) adherence to antiretroviral treatment on long-term virological response in HIV-infected patients: results from the 11-year followup of the ANRS CO8 APROCO-COPILOTE cohort C. Protopopescu, M.P. Carrieri, F. Raffi, L. Hardel, A. Sobel, C. Perronne, C. Jadand, J. Pierret, B. Spire, C. Leport, the ANRS CO8 APROCO-COPILOTE Study Group France HIV patient preferences for simplified treatment regimens and impact on selfrated treatment adherence M. Orme, A. Miners, C. Sabin, F. Rogatto, G. Reilly, R. Perard Physical and sexual violence independently correlated with reduced adherence to ART among women sex workers living with HIV in Vancouver, K. Deering, S. Goldenberg, O. Amram, J. Chettiar, S. Guillemi, R. Nicoletti, J. Montaner, S. Dobrer, P. Nguyen, K. Shannon PEB294-B295 Complementary and traditional medicines TUPEB295 Thalidomide lead to an increase in T cell activation and inflammation on antiretroviral naive HIV-infected individuals T.R.C. Vergara, A.M. Da-Cruz, J.R. Santos- Oliveira, N.C. Martos, L.B. Giron, M.L. Silva- Freitas, L.A. Cherman, M.S. Treitsman, A. Chebabo, M.C.A. Sucupira, R.S. Diaz Brazil Effects of short-term probiotic ingestion in children with HIV-1 infection H. Ichimura, A. Ishizaki, X. Bi, L.V. Nguyen, K. Matsuda, H.V. Pham, C.T.T. Phan, K. Ogata, T.T.T. Giang, T.T.B. Phung, T.T. Nguyen, A.N. Pham, D.T.K. Khu Japan PEB296-B298 Curative interventions (including those aimed at reservoir depletion) 7 / 17

8 TUPEB296 TUPEB297 TUPEB298 PEB299 TUPEB299 Reduction in total HIV-1 proviral DNA following re-boost immunizations using the peptide-based therapeutic vaccine candidate, Vacc-4x, during ART J.K. Rockstroh, D. Asmuth, G. Pantaleo, B. Clotet, D. Podzamczer, J. van Lunzen, K. Arastéh, R. Mitsuyasu, B. Peters, A. Lazzarin, D. Jolliffe, M. Ökvist, K. Krogsgaard, A. Mørk, M.A. Sommerfelt Norway A feasibility study of weight-based pegylated IFN-a2b immunotherapy to target persistent HIV-1 on ART L. Azzoni, E. Papasavvas, K.M. Lynn, A. Kapalko, L. Lalley-Chareczko, F. Aberra, P. Tebas, K.C. Mounzer, J.R. Kostman, Q. Li, L.J. Montaner Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-infected individuals A. Cash, A. Capoferri, D. Xu, H.L. Mchugh, O. Laeyendecker, S. Sakoian, L. Tony, C. Bullen, C. Pohlmeyer, P. Pham, J. Lai, J.E. Gallant, R.F. Siliciano, C. Flexner, K. Pratz, M. Levis, R.J. Jones, Y.L. Kasamon, R.F. Ambinder, C.M. Durand Clinical approaches to drug and alcohol dependence treatment: harm reduction Impact of opioid substitution therapy on antiretroviral therapy: a systematic review and meta-analysis A. Low, G. Mburu, C. Davies, C. French, M. May, S. McLean, T. Rhodes, L. Platt, A. Guise, P. Vickerman TUPEB305 TUPEB306 TUPEB307 PEB308 TUPEB308 Adolescents are at higher risk of attrition from HIV care: results from a cohort study in Ethiopia D. Jerene, W.A. Taye, K.T. Gari, L. Wissow, A.J. Ruff Ethiopia 12-month response to early LPV-based antiretroviral therapy in West-African children treated before the age of 2 years, the MONOD ANRS cohort C. Amani-Bossé, D. Dahourou, K. Malateste, M. Coulibaly, M. Timité-Konan, N. Méda, A. Emième, R. Ouédraogo, C. Devaux, P. Van de Perre, S. Blanche, V. Leroy, MONOD ANRS Study Group France Determinants of durability of first-line ART regimen and time from first-line failure to second-line ART initiation. The IeDEA paediatric West African Database (pwada) S. Desmonde, F. Eboua, K. Malateste, F. Dicko, D.K. Ekouevi, S. N'Gbeche, F. Koueta, H. Signate Sy, L. Renner, S. Koumakapi, V. Leroy France Clinical issues in men who have sex with men Hospitalisation and predictors of morbidity in community-based cohorts of HIV- positive and -negative gay and bisexual men C.L. Moore, A.E. Grulich, G. Prestage, H.F. Gidding, F. Jin, L. Mao, K. Petoumenos, I.M. Poynten, I.B. Zablotska, M.G. Law, J. Amin PEB309-B312 Clinical issues in people who use drugs PEB300-B302 Diagnosis of HIV disease in children and adolescents (including early infant diagnosis) TUPEB300 TUPEB301 TUPEB302 TUPEB303 TUPEB304 Adolescent representation among clients accessing HIV testing at a large tertiary facility in north-central A. Ibrahim, S. Erekaha, C. Onuchukwu, M. Essen, V. Tepper, M. Charurat, H. Swomen, W. Blattner, N.A. Sam-Agudu Loss to follow-up along the early infant diagnosis care continuum in Kenya K. Clark, V. Okoth, B. Gautney, S. Khamadi, K. Goggin, R. Wafula, I. Mukui, C. Martin, S. Finocchario-Kessler Low birth HIV infection rate in infants from high-risk-for-transmission pregnancies in J. Maritz, A. Nelson, V. Cox, G. van Zyl, W. Preiser, G. van Cutsem, H. Rabie, L. Frigati, J. Bernheimer, J. Giddy, M. Cotton PEB303-B307 ARV management strategies: children and adolescents cohort studies High sensitivity CRP (hscrp) levels in long-term survivors of perinatal HIV infection K. Kancherla, S. Kalyanam, N. Desai Durability of first-line antiretroviral therapy (ART) in children in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) R.L. Goodall, I.J. Collins, T. Childs, C. Foster, L. Ene, C. Smit, C. Kahlert, A. Judd, D. Gibb, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord TUPEB309 TUPEB310 TUPEB311 TUPEB312 Track C > TUPEC499 Factors associated with ART adherence and plasma HIV-1 RNA suppression among crack cocaine users in Vancouver, K. Hayashi, E. Wood, P. Nguyen, S. Guillemi, R. Hogg, J. Montaner, T. Kerr, M.-J. Milloy Advanced liver fibrosis and mortality of HIV/HCV co-infected patients with alcohol use disorders P. Zuluaga, D. Fuster, F. Bolao, A. Sanvisens, I. Rivas, M. Torrens, J. Tor, R. Muga Discharge against medical advice from the HIV ward at St. Paul's Hospital, Vancouver, British Columbia, from J.H. Kremer, M. Hull, P. Phillips, D. Jaworsky, Z. Cui, N. Oliveira, R.S. Hogg, J. Montaner Prescription opioid injection is strongly linked with illicit drug-related vulnerability and plasma HIV-1 RNA viral load detectability among HIV-positive illicit drug users in a Canadian setting S. Lake, T. Kerr, R. Hogg, S. Guillemi, H. Dong, J. Montaner, E. Wood, M.-J. Milloy PEC499-C501 PEP Prevention Science Delayed HIV seroconversions in patients receiving post-exposure prophylaxis (PEP) L. Leal, B. Torres, A. León, A. Inciarte, C. Lucero, V. Díaz-Brito, J.M. Gatell, F. García 8 / 17

9 TUPEC500 TUPEC501 TUPEC502 TUPEC503 TUPEC504 TUPEC505 Post-exposure prophylaxis outcomes for survivors of sexual assault in resource poor settings: evidence from rural South Africa C.R. Carty, E. Toska, T. Mukaro, F. Nicholson Awareness of post-exposure prophylaxis (PEP) among a cohort of gay, bisexual and other men who have sex with men (MSM) in Vancouver, A. Rich, M. Hull, N.J. Lachowsky, Z. Cui, P. Sereda, K. Stephenson, M. Thumath, E.A. Roth, R.S. Hogg, D. Moore PEC502-C521 PrEP TUPEC506 TUPEC507 TUPEC508 TUPEC509 Willingness to receive PrEP among HIVuninfected Chinese MSM who are users of a popular geosocial networking application H.T.H. Wong, S.S. Lee, D.P.C. Chan Hong Kong, SAR of China PrEP in real-life settings: good adherence and no increase in high-risk behavior R. Thomas, C. Galanakis, D. Longpré, J.-P. Kerba, L. Charest, S. Lavoie, E. Huchet, D. Murphy, B. Trottier, N. Machouf Concerns and benefits of PrEP: lessons from the national PrEP demonstration project formative study in Y. Nancin Dadem, J. Idoko, M. Folayan, O. Grace Kolawole, J. Anenih, E. Alhassan HIV pre-exposure prophylaxis (PrEP) product preference among women in the VOICE-D (MTN-003D) study E. Luecke, H. Cheng, K. Woeber, T. Nakyanzi, O. Munaiwa, A. van der Straten Patient-provider communication about sexual behaviors and pre-exposure prophylaxis: results from a national online survey of men who have sex with men in the D.S. Krakower, C.E. Oldenburg, M.J. Mimiaga, D. Novak, J.G. Rosenberger, S. Elsesser, K.H. Mayer Absence of sexual behavioral disinhibition in a PrEP adherence trial: considerations for medical providers who prescribe PrEP for men who have sex with men (MSM) S. Elsesser, K. Biello, S. Taylor, J. Tomassilli, S. Safren, K. Mayer Significant increases in HIV pre-exposure prophylaxis (PrEP) uptake in Boston, a Boston Community Health Center in 2014: who are the recent users? K. Mayer, D. Krakower, K. Levine, C. Grasso, M. Gelman Pre-exposure prophylaxis (PrEP) knowledge and use in a population-based sample of younger Black men who have sex with men (YBMSM) in Chicago A. Khanna, S. Michaels, B. Skaathun, E. Morgan, L.E. Young, P. Schumm, J.A. Schneider, UConnect Study Group TUPEC510 TUPEC511 TUPEC512 TUPEC513 TUPEC514 TUPEC515 TUPEC516 TUPEC517 TUPEC518 TUPEC519 PrEP in the real world: implementation of PrEP in a medium-sized city community health clinic R. Corales, S.-R. Chen, S. Holt, A. Zuppelli, J. Ritzler, J. Roberts, W. Schaefer, M. Mancenido, W. Valenti Fertility intentions, pregnancy and PrEP use in African HIV serodiscordant couples R. Heffron, K. Thomson, C. Celum, N. Mugo, E. Katabira, E. Bukusi, S. Asiimwe, K. Ngure, N. Bulya, J. Odoyo, E. Tindimwebwa, D. Donnell, J. Baeten, The Partners Demonstration Project Team Differences in HIV pre-exposure prophylaxis use and intention to use between stimulant and alcohol-using men who have sex with men in Boston, United States C. Oldenburg, J. Mitty, K. Biello, E. Closson, K. Mayer, M. Mimiaga Text messaging responses correlate with tenofovir-diphosphate dried blood spot concentrations among men who have sex with men on pre-exposure prophylaxis J. Blumenthal, D. Moore, S. Jain, K. Corado, M. Dube, J. Young, S. Sun, P. Anderson, S. Morris, R. Haubrich, California Collaborative Treatment Group PrEP utilization estimates in I. Zablotska, G. Prestage, A.E. Grulich HPTN 067 ADAPT: 'PrEP Ubuntu' and experiences with open-label PrEP among n women M. Wallace, L.-G. Bekker, S. Roux, M. Atujuna, E. Sebastian, B. Dye, V. Elharrar, R. Grant, R. Amico HIV evolution in breakthrough infections in a human trial of oral PrEP with FTC/TDF S. Ruone, L. Paxton, T. Mclaurin, A. Taylor, W. Heneine, J.T. Brooks, J.G. Garcia-Lerma HIV-negative male couples' attitudes about pre-exposure prophylaxis (PrEP), and PrEP use within the context of their relationships and sexual agreements J. Mitchell, J.-Y. Lee, J. Bauermeister, C. Woodyatt, S. Patrick, S. Lim, P. Sullivan, R. Stephenson Risk compensation among men who have sex with men (MSM) in Southern California following the initiation of preexposure prophylaxis (PrEP) J. Milam, S. Jain, D. Moore, E. Daar, M. Dube, J. Young, J. Blumenthal, S. Sun, R. Haubrich, S. Morris, CCTG 595 and 597 Study Teams Reasons for accepting or declining HIV pre-exposure prophylaxis in a diverse black US population H. Kwakwa, R. Wahome, D. Sturgis, N. Mvula, S. Bessias 9 / 17

10 TUPEC520 TUPEC521 TUPEC522 Individual and sexual network characteristics are associated with HIV serodisclosure in the global iprex study J.C. Hojilla, M. Mehrotra, V. Mcmahan, L.-G. Bekker, J.V. Guanira, B. Hoagland, S. Hosek, K.R. Amico, D. Glidden, R. Grant, iprex Study Team Validation of a Truvada for PrEP algorithm using an electronic medical record T. MacCannell, S. Bush, S. Verma, V. Shvachko, K. Rawlings, R. Mera PEC522-C523 Microbicides (including vaginal and rectal microbicides) TUPEC523 TUPEC524 Safety of cervical and vaginal biopsies in microbicide and contraceptive research A. Thurman, T. Kimble, A. Nel, B. Chen, S. Achilles, M. Keller, I. McGowan, T. Hirbod, R. Kaul, K. Linton, J. Schwartz, G. Doncel, C. Mauck Pharmacokinetics of tenofovir and emtricitabine delivered by vaginal tablets C. Mauck, A. Thurman, M. Keller, D. Archer, T. Kimble, A. Kashuba, C. Sykes, D. Friend, G. Doncel PEC524-C525 Barriers and facilitators to adherence to biomedical HIV prevention strategies TUPEC525 TUPEC526 Factors linked to transitions in adherence to antiretroviral therapy among HIVinfected illicit drug users in a Canadian setting B. Joseph, T. Kerr, C. Puskas, J. Montaner, E. Wood, M.-J. Milloy The impact of health literacy and physician-patient dynamics on health outcomes in adult HIV patients A. Wawrzyniak, A. Falcon, A. Parra, A. Rodriguez PEC526-C528 Approaches to improving adherence to prevention interventions TUPEC527 TUPEC528 Prevalence and correlates of nondisclosure of maternal HIV status in Kenya J. Kinuthia, C. McGrath, B. Odeny, B. Singa, A. Langat, A. Katana, L. Nganga, J. Pintye, G. John-Stewart Kenya African women's perceptions of honesty and dishonesty about product use adherence in the context of HIV prevention research during the VOICE (MTN-003) trial E. Montgomery, P. Musara, K. Woeber, J. Etima, B. Mensch, A. van der Straten Difficulty accessing addiction treatment predicts injection initiation among streetinvolved youth in a Canadian setting K. DeBeck, T. Kerr, H. Dong, J. Montaner, E. Wood PEC529-C531 Prevention for the general population TUPEC529 TUPEC530 TUPEC531 TUPEC532 How do HIV-negative individuals in sub- Saharan Africa change their sexual risk behaviour upon learning their serostatus? A systematic review S. Ramachandran, N. Condie, M. Pickles, S. Mishra Development and initial validation of an instrument to measure beliefs among women in Puerto Rico about biomedical interventions and the biological factors that facilitate inbound and outbound HIV transmission K. Fitzgerald, J. Martínez González Puerto Rico Factors associated with uptake of HIV counseling and testing in Cross River State, C. Oyom, M. Mbukpa, O. Idogho, G. Eluwa, A. Oginni PEC532-C540 Prevention for youth and adolescents TUPEC533 TUPEC534 TUPEC535 TUPEC536 TUPEC537 TUPEC538 HIV decline associated with changes in risk behaviors among vulnerable young people in Nepal: analysis of populationbased HIV prevalence surveys between K. Deuba, D. Kumar Karki, A.M. Ekström, G. Tomson, G. Marrone Sweden Using peer to peer approach to promote uptake of HIV/SRH services among young people (10-24 years): experience with young key populations (YKPs) in 3 central districts of W. Musubika, D. Bukenya, H. Ntale, P. Mpinga, R. Egadu, S. Kadokech, S. Nabadda, R. Nabossa Street culture, survival and HIV risk among street-connected girls in a resource-limited setting J. Wachira, A. Kamanda, L. Embleton, V. Nanyu, D. Ayuku, P. Braitstein Understanding opportunities for HIV prevention and care for street connected children and youth in western Kenya L. Embleton, J. Wachira, A. Kamanda, V. Naanyu, S. Winston, D. Ayuku, P. Braitstein Effects of the PREPARE multi-component, school-based HIV prevention programme on adolescent sexual risk behavior and access to condoms, contraception and HIV testing: cluster randomized controlled trial (RCT) C. Mathews, S.M. Eggers, L.J. Townsend, L.E. Aarø, P.J. de Vries, A.J. Mason-Jones, P. De Koker, T. Mcclinton Appollis, J. Koech, Y. Mtshizana, A. Wubs, N.T.D. Naledi, H. De Vries Correlates of intimate partner violence perpetration among young urban Tanzanian men M. Mulawa, H.L.M. Reyes, V. Foshee, S. Martin, L. Kajula, S. Maman Optimising adolescent HIV care in a large Kenyan care and treatment centre N. Gitahi-Kamau, S. Ilovi, L. Njagi, E. Njuguna, K. Mutai, I. Katei, I. Inwani, J. Mecha Kenya 10 / 17

11 TUPEC539 TUPEC540 TUPEC541 Towards adolescent friendly voluntary medical male circumcision services: older adolescents report relatively less satisfaction with counseling D. Boyee, E. Peacock, K. Andrinopoulos, M. Plotkin, A. Hellar, H. Mahler, E. Edouard, E. Mlanga, R. Kisendi Tanzania, United Republic of The impact of food insecurity on sexual HIV risk negotiation with clients among youth sex workers living with and affected by HIV D. Barreto, K. Shannon, C. Taylor, S. Dobrer, J. Brown, S. Goldenberg, K. Deering PEC541-C551 Prevention for people who use drugs, including harm reduction TUPEC542 TUPEC543 TUPEC544 TUPEC545 TUPEC546 TUPEC547 Characteristics of drug use in coastal and mainland Tanzania: a mixed methods, rapid assessment in 12 regions J. Tiberio, A. Ngonyani, Y.I. Laurent, A. Msami, M. Makumbuli, S. Mwankemwa, J. Ndayongeje, E. Matiko, S. Welty, M. Morris Tanzania, United Republic of Evidence-based recommendations for essential and novel HIV prevention and harm reduction services for people who use drugs in and are at risk for HIV, HCV and other harms C. Strike, T.M. Watson, S. Hopkins, H. Gohil, M. Miskovic, P. Leece, S. Robinson, C. Arkell, L. Challacombe, Working Group on Best Practices for Harm Reduction Programs in Urgent need for harm-reduction interventions in Mozambique: results from the Integrated Biological and Behavioral Surveillance Survey among people who inject drugs E. Teodoro, M. Boothe, C. Sema Baltazar, P. Young, H. Frank, I. Sathane, M.L. Gouveia, R. Horth Mozambique Seek, test, treat and retain (STTR) for people who inject drugs (PWID) in Kenya: findings from the third intervention period of a stepped wedge study J. Lizcano, A. Kurth, C. Cleland, P. Cherutich More vulnerability, more risk: findings from a cross-sectional qualitative study on the multiple vulnerabilities experienced by people who inject drugs (PWID) in Bihar and Manipur, India V. Arumugam, K. Biswas, C. Sharma, F. Joseph, S.W. Beddoe, S. Mehta, J. Robertson India Reach them early: identifying risk behaviours after onset of injecting to reduce sharing of injecting equipment: findings from the Hridaya drug use pattern assessment in India V. Arumugam, J. Robertson, K. Biswas, C. Sharma, F. Joseph, S.W. Beddoe, S. Mehta, A. Ambekar, U. Sharma, R.K. Raju, S. Singh, A. Biswas India Effective services for HIV prevention among people who inject drugs (PWIDs) in Ukraine I. Sazonova, T. Mykhalchuk, T. Salyuk, O. Varetska Ukraine TUPEC548 TUPEC549 TUPEC550 TUPEC551 TUPEC552 Exploring HIV risks and treatment outcomes among people who use drugs enrolled in unregulated recovery house programs in British Columbia, 's Lower Mainland region: a qualitative study R. McNeil, T. Kerr, S. Anderson, L. Maher, W. Small Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modelling P. Vickerman, L. Platt, E. Jolley, T. Rhodes, M. Kazatchkine, A. Latypov HIV risk factors associated with risky and illegal income generation among streetinvolved youth in a Canadian setting T. Cheng, T. Kerr, P. Nguyen, E. Wood, K. DeBeck Defining public disorder: conceptual implications for HIV prevention efforts D. Werb, D. Fast PEC552-C560 Prevention for male, female and transgender sex workers TUPEC553 TUPEC554 TUPEC555 TUPEC556 TUPEC557 TUPEC558 Interventions for commercial sexual workers: lessons and challenges from Rakai, J.L. Ssembatya, G. Nakigozi, J.B. Ssemanda, R. Kairania, E. Kato, F. Nalugoda, J. Kagaayi, D. Serwadda, N. Sewankambo, M.J. Wawer, R.H. Gray ILO Understanding high HIV risk behavior, gender identity, stigma and violence among transgender women in urban R. King, J. Nanteza, Z. Sebyala, T. Poteat, R. Apondi, W. Hladik Transactional sex and the challenges to safer sexual behaviors: a study among male sex workers in Chennai, India B. Thomas, K. Biello, E. Closson, P. Navakodi, A. Dhanalakshmi, S. Menon, K. Mayer, S. Safren, M. Mimiaga Prevalent syphilis predicts HIV acquisition among men who have sex with men who received money, or gifts in exchange for sex, Bangkok, Thailand S. Pattanasin, W. Wimonsate, P. Luechai, K. Pancharoen, W. Sukwicha, S. Lertpruek, J. Tongtoyai, P. Sirivongrangson, E.F. Dunne, T.H. Holtz Thailand Concealment and stigma in the context of adherence to ARV therapy amongst female sex workers in Bamenda, Cameroon, a qualitative report R.T. Nyenti, F.P. Ijang, N. Atiabet, G. Njoyah, FSW-REACH OUT Study Group Cameroon Determinants of non-condom use among female sex workers in Iran: findings of the first national bio-behavioural study M. Karamouzian, A. Mirzazadeh, H. Sharifi, A. Sedaghat, M. Shokoohi, A. Haghdoost Iran, Islamic Republic of Testing for HIV among female sex workers in Iran; findings of the first national bio-behavioural survey in 2010 H. Sharifi, A. Mirzazadeh, M. Karamouzian, M. Shokoohi, A. Sedaghat, A. Haghdoost Iran, Islamic Republic of 11 / 17

12 TUPEC559 TUPEC560 TUPEC561 Induced abortion among female sex workers in Iran: findings of the first national bio-behavioural study in 2010 H. Sharifi, M. Karamouzian, A. Mirzazadeh, A. Sedaghat, M. Shokoohi, A. Haghdoost Recent incarceration correlated with reduced access to HIV prevention in a longitudinal study of sex workers who inject drugs in a Canadian urban centre M.E. Socías, K. Shannon, M. Horton, P. Nguyen, T. Lyons, R. Martin, M. Mannoe, K. Deering PEC561-C566 Prevention for MSM TUPEC562 TUPEC563 TUPEC564 TUPEC565 TUPEC566 TUPEC567 The emergence of undetectable viral load as a HIV risk reduction strategy by n gay and bisexual men who have condomless sex with casual partners M. Holt, T. Lea, L. Mao, I. Zablotska, G. Prestage, J. de Wit Awareness & utilization of HIV prevention innovations among men who have sex with men in Seattle J. Hood, S. Buskin, E. Barash, D. Katz, J. Dombrowski, M. Golden When and how male couples form a sexual agreement in their relationship: qualitative findings toward development of a tailored online HIV prevention 'toolkit' for at-risk HIV-negative male couples J. Mitchell, J.-Y. Lee, J. Bauermeister, C. Woodyatt, S. Patrick, S. Lim, P. Sullivan, R. Stephenson Awareness and willingness to take preexposure prophylaxis (PrEP) among men who have sex with men and transgender women: preliminary findings from the PrEP Brasil study B. Hoagland, V.G. Veloso, R.B. De Boni, J.V. Madruga, E.G. Kallas, N.M. Fernandes, R.I. Moreira, A.Y. Liu, B. Grinsztejn Brazil Community mobilization intervention with men who have sex with men (MSM) increases uptake of regular HIV-testing in : 12-month impact evaluation results from project Boithato T. Lane, T. Osmand, A. Marr, S. Shade, N. Mlotshwa, A. Bilankulu, R. Gaobepe, T. Sandfort, H. Struthers, S. Kegeles, J. McIntyre An event-level analysis of substance use, relational, and psychosocial factors affecting condom use during anal intercourse among self-identified HIVnegative and unknown status gay and other MSM in Vancouver, British Columbia N. Lachowsky, J. Jollimore, A. Rich, Z. Cui, P. Sereda, A. Lal, R. Hogg, D. Moore, E. Roth PEC567-C568 Prevention for transgender persons Prevalence and correlates of injection of industrial silicone among transgender women in Argentina M.E. Socías, T. Kerr, B.D.L. Marshall, I. Arístegui, C. Frola, P. Cahn, O. Sued Argentina TUPEC568 PEC569 TUPEC569 TUPEC570 Transgenders in Ukraine: understudied and underserved R. Kulchynska, T. Saliuk, O. Trofimenko, A. Meteliuk, M. Gates Prevention for immigrants, mobile and displaced populations Assessment of HIV associated risk behaviour among internally displaced persons (IDPs) in Northern C. Ifekandu, U. Bukar, E. Jegede PEC570-C573 Prevention for HIV serodiscordant couples TUPEC571 TUPEC572 TUPEC573 PEC574 TUPEC574 PEC575 TUPEC575 TUPEC576 Implementation of HIV discordant couple care and treatment program in a Kenyan referral hospital N. Gitahi-Kamau, J. Kiarie, S. Eshiwani, K. Mutai, L. Njagi, S. Ilovi, J. Mecha Kenya Couples testing and immediate antiretroviral therapy among serodiscordant couples in Vietnam: implementation study in resource-limited settings affected by drug use D.D. Bui, T.N. Do, T.L.A. Tong, K.T. Duong, T.L. Pham, K.A. Lai, X.C. Hoang, H.A. Nguyen, T.V. Vu, T.X.L. Truong, T.T.V. Nguyen, V. Dao, M.H. Do, A. Suthar, P. Nadol, S. Lyss, T.L. Nguyen, M. Kato Vietnam Healthcare providers' understanding of HIV sero-discordance in and : implications for HIV prevention counselling R.M. Greener, C. Milford, F.N. Mosery, F. Bajunirwe, L. Pillay, L. Moore, C. Ng, J. Kastner, R. Rifkin, J.A. Smit, D.R. Bangsberg, A. Kaida, L.T. Matthews Community cultural beliefs and disclosure to primary sexual partners among women living with HIV in Brazil, Thailand and Zambia: results from HPTN063 B. Ojikutu, S. Pathak, S. Li, K. Mayer, S. Safren, HIV Prevention Trials Network 063 Prevention for other vulnerable populations Perceptions of HIV burden and risk among Lake Victoria fishing communities: a qualitative study V.C. Lee, T. Saliku, Z. Gura, E. Zielinski- Gutierrez Kenya Prevention during acute and recent infection Influence of suspected source of infection on disclosure among people with acute HIV in Malawi S. Hino, C. Grodensky, G. Hamela, C. Massa, C. Golin, S. Rutstein, K. Smith, L. Christmas, W. Miller, G. Kamanga, S. Phiri, A. Pettifor PEC576-C580 Prevention among HIV-infected individuals Prevention strategies during anal intercourse and prevention-related attitudes of HIV-positive gay, bisexual and other MSM in Vancouver, British Columbia N. Lachowsky, T. Howard, Z. Cui, P. Sereda, A. Rich, A. Lal, E. Roth, R. Hogg, D. Moore 12 / 17

13 TUPEC578 TUPEC579 TUPEC580 TUPEC581 Ongoing HIV-transmission risks and factors associated with HIV transmission risks among young people living with HIV (YPLHIV) in J.B. Zieman, C. Banura, R. Ampwera, D. Amanyire, M. Elang, G. Caswell, J. Okal, E. Yam, L. Vu Attitudes and preferences about cervical cancer screening among women living with HIV in Peru I. Alva, A. Mühlbach, C. Diaz, E. Juárez, J.L. Castro, M. Blas, G. Mburu, P. García, R. Cabello Peru HIV-related stigma and depression among newly diagnosed HIV-infected men who have sex with men, in China J. Tao, A.M. Kipp, Y. Liu, C. Zhang, Y. Ruan, L. Yin, K.R. Amico, Y. Shao, H.-Z. Qian, S.H. Vermund PEC581-C583 Prevention in other institutional settings (including workplace / school / prison / army) TUPEC582 TUPEC583 TUPEC584 HIV/AIDS in prison: a global systematic review of HIV incidence and AIDS related mortality K. Dolan, B. Moazen, A. Noori, S. Rahimzadeh, F. Farzadfar, F. Hariga Prevalence and correlates of occupational needle-stick injuries among active duty police officers in Tijuana, Mexico M.L. Rolón, E. Patiño, L. Beletsky, J. Arredondo, T. Rocha, D. Abramovitz, V.M. Alaníz Morales, A. Bañuelos Pérez, M.G. Rangel Gómez, S.A. Strathdee Endowment training intervention: changing attitudes toward opioid substitution therapy in 30 minutes M. Polonsky, F. Altice PEC584-C587 Collectivization, mobilization, stigma reduction programmes TUPEC585 TUPEC586 TUPEC587 Stigmatized health care: a challenging issue for Iranian HIV+ patients N. Zarei, H. Joulaei, M. Amini Lari Iran, Islamic Republic of Opinions and experiences of HIV-status disclosure to sex partners: a qualitative study with gay men in Lima, Peru C. Sandoval, L. Najarro, K. Konda Development and reliability of scales to measure stigma among men who have sex with men and female sex workers in West Africa: tools for stigma reduction programmes A. Grosso, S. Ketende, G. Ouedraogo, S. Anato, O. Ky-Zerbo, V. Pitche, E. Papworth, S. Baral Determinants of stigmatization of people living with HIV/AIDS in Burkina Faso M. Kaboré, H. Badolo, N. Sawadogo, Y.J. Drabo, N. Méda Burkina Faso PEC588-C593 Policy-level HIV interventions including legal-policy reform TUPEC588 TUPEC589 TUPEC590 TUPEC591 TUPEC592 TUPEC593 TUPEC594 Assessing changes in HIV-related legal and policy environments in sub-saharan Africa L. Ferguson, S. Gruskin, I. Henry, A. Nicholson, A. Saha, T. Sellers A global analysis of the role of lay providers in national HIV testing and counseling policies D. Flynn, C. Johnson, A. Sands, V. Wong, R. Baggaley Criminalization of HIV transmission in France: knowledge of and concerns about HIV-related court-case verdicts in a representative sample of people living with HIV (ANRS VESPA2 survey) M. Suzan-Monti, B. Demoulin, M. Celse, R. Dray-Spira, F. Lert, B. Spire, ANRS VESPA2 Study Group France Policy and legal challenges and opportunities for HIV and drug abuse prevention among migrant tourism workers in the Dominican Republic M. Padilla, N. Varas-Diaz, J. Colon Burgos, A. Matiz-Reyes Gender differences in meeting legal obligations to disclose HIV status within a cohort of HIV-positive illicit drug users in Vancouver S. Patterson, A. Kaida, P. Nguyen, J.S. Montaner, G. Ogilvie, R.S. Hogg, M.-J. Milloy Supporting policy-level action for improved health outcomes in Zimbabwe C. Zinyemba, A. Mahomva, E. Tumbare, A. Mushavi Zimbabwe PEC594-C595 Community involvement in biomedical prevention TUPEC595 Track D > PED761- D763 TUPED761 Facilitating community-led action for optimal uptake of prevention of mother to child transmission of HIV (PMTCT) services in vulnerable communities: the Elizabeth Glaser Pediatric AIDS Foundation-Zimbabwe community engagement program C. Zinyemba, E. Tumbare, E. Chinake, W. Ushamba, T. Gutuza, A. Mahomva Zimbabwe Engaging MSM key opinion leaders to create and sustain HIV and STIs services for a trusted community health centre Lagos, E. Shoyemi, J. Njab, S. Adebajo, D. Offie, P.L. Oladimeji, B. Keshinro Implementation Science Integration of prevention interventions with care/treatment Effective use of task shifting in strengthening 4 symptom screening for TB disease among PLHIV in rural clinics in Northern G. Egesimba, N. Nwokedi, E. Nwabueze, A. Abdulraheem, J. Kolin, A. Etsetowaghan 13 / 17

14 TUPED762 Integrating direct provision of ART into TB services to increase ART uptake among TB-HIV co-infected clients in south west ( ) TUPED772 The demand for CD4 testing, viral load and early infant diagnostic testing in low and middle income countries will grow strongly between now and 2018 TUPED763 PED764- D772 TUPED764 TUPED765 TUPED766 TUPED767 TUPED768 E. Natumanya Kajungu, M. Namubiru, C. Nerima, J. Seclen-Palacin, J. Asiimwe, E. Bitarakwate New strategies to increase HIV case finding in hard to reach populations P. Smyrnov, A. Korobchuk, S. Muth, O. Denisiuk, D. Paraskevis, G. Nikolopoulos, J. Schneider, S. Friedman Ukraine Methods to improve provider quality, supply and tailoring of services Are women enrolled in the PMTCT program breastfeeding their infants? Findings from a PMTCT electronic database in Zimbabwe E.A.J. Tumbare Machakaire, E. Tachiwenyika, A. Mahomva, J. Mabuku, C. Muchuchuti, N. Mahachi Zimbabwe Quality of care and treatment for HIVpositive patients in two rural health districts in sub-saharan Africa S. Nahrgang, M. Sarker, A. Sié, H. Masanja, H.W.F. Neuhann, ARVMAC WHO Determinants of forecast accuracy for paediatric antiretroviral drugs in Kenya S. Njogo, G. Osanjo, E. Guantai Kenya HIV-infected adolescent and caregiver experiences of HIV stigma and discrimination in Kenya L. Fischer, W. Nyandiko, M. Scanlon, M. McHenry, V. Naayu, R. Vreeman What factors are critical in improving client satisfaction with PMTCT services in Zimbabwe? Findings from a client satisfaction survey PED773- D778 TUPED773 TUPED774 TUPED775 TUPED776 TUPED777 V. Habiyambere, J. Perriens, M. Perez- Gonzales, B. Dongmo-Nguimfack, Diagnostic Access Initiative Forecasting Technical Working Group WHO Healthcare workers and volunteers: training, mentoring, retaining, task shifting, safety Community Lay Cadres' contributions and over task-shifting in expansion of antiretroviral therapy to rural health centres in Zambia K. Komada, M. Chirwa, C. Msiska, V. Chipeta, K. Chibwe, P. Nambara, P. Mwaba, N. Kayama, C. Dube, A. Mwango Zambia Reductions in annual ART costs in : implications for future ART resource needs and task-shifting L. Vu, L. Ssali, L. Buzaalirwa, S. Waliggo, B. Zieman, N. Jani, S. Okoboi, M. Etukoit, P. Kiyingi, J. Nsamba, S. Kalibala The effectiveness of men who have sex with men (MSM) sensitivity training for n health care providers (HCPs) C. Ifekandu, S. Sangowawa, A. Oginni, D. Iriaye, I. Suleiman, J. Njab, B. Abdullahi, S. Adebajo HIV training program is effective to increase HIV knowledge among health care workers in Georgia O. Chokoshvili, N. Gulua, N. Chkhartishvili, M. Tsintsadze, N. Chokoshvili, T. Tsertsvadze Georgia Taking lessons learned in the implementation of a clinical mentorship program to increase the confidence of nurses to initiate ART, in support of the roll out of Option B+ B. Mutede, E. Tachiwenyika, R. Musarandega, B. Khabo, M. Mhangara, E. Tumbare Zimbabwe T. Moga, T. Ncomanzi, B. Mutede, T. Nyamundaya, E. Tumbare Zimbabwe TUPED769 Congestion in urban HIV treatment clinics in Lusaka, Zambia: an assessment of factors to inform decongestion solutions TUPED778 Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: a feasibility study in rural Lesotho TUPED770 TUPED771 S. Moberley, A. Mwango, F. Mpasela, H. Subramaniam, M. Prust, M. Prescott, G. Kadimba, C. Mbewe, B. Chibuye, J.W. Van den Broek, E. McCarthy Zambia Descriptive case study of a quality improvement intervention to implement evidence-based HIV care and improve HIV care and treatment outcomes in 17 British Columbia sites C. Clarke, T. Cheng, K. Reims, C. Steinbock, S. Milligan, M. Thumath, D. Hall, E. Kanigan, J. Postnikoff, J. Toy, R. Undi, R. Barrios Forecasted demand for ARV medicines in low and middle income countries up to the end of 2018 V. Habiyambere, J. Perriens, B. Dongmo- Nguimfack WHO PED779 TUPED779 PED780- D788 TUPED780 K. Luzinda, V. Buard, I. Damiani, S. Sedlimaier Ouattara, M. Kuleile, T. Mots'oane, M. Leqheka, G. Van Cutsem, A. Shroufi Demand generation for HIV services Overcoming burden of seasonality in scaling up voluntary medical male circumcision: a case study from Tanzania H.R. Mahler, E. Gold, D. Boyee, A. Hellar, J. Lija, E. Mlanga, E. Njeuhmeli, K. Curran Tanzania, United Republic of Strategies to increase linkage to HIV care Implementing access to care interventions: structural, organizational and personnel barriers and facilitators S. Kinsky, C. Maulsby, K. Jain, V. Charles, M. Riordan, D. Holtgrave 14 / 17

15 TUPED781 Peer navigation in : addressing stigma and psychosocial barriers to engagement in HIV services TUPED792 Health care workers have changed their bad language : When the patient's voice is heard TUPED782 W.T. Steward, J. Sumitani, J. Morris, M.-J. Ratlhagana, M.E. Moran, J. Grignon, S. Barnhart, J. Tumbo, J. Gilvydis, S.A. Lippman Implementation of a rapid referral pathway to HIV treatment for gay men and MSM diagnosed with acute HIVinfection in sexual health clinics in British Columbia M. Thumath, D. Moore, M. Hull, B. Brownrigg, I. Sandstra, G. Ogilvie TUPED793 G. Mbita, T. Kiwale, R. Ally, E. Mshana, A. Shirima, C. Kimario, J. Macha, A.B. Ntogwisangu, T. Mtambalike, G. Antelman, R. Van den Ven Tanzania, United Republic of A community-led health campaign in a low-resource rural setting in Western J. Kabami, D. Kwarisiima, G. Chamie, E. Biira, P. Ssebutinde, M. Petersen, E.D. Charlebois, M.R. Kamya, D.V. Havlir, T.D. Clark TUPED783 Factors associated with ART initiation among HIV-infected participants in the Bangkok men who have sex with men cohort study, W. Wimonsate, A. Sriporn, P. Luechai, K. Pancharoen, S. Lertpruek, S. Yafant, S. Winaitham, T. Holtz, A. Chitwarakorn, E. Dunne, T. Chemnasiri Thailand TUPED794 Engaging the community to improve delivery and uptake of TB HIV collaborative services at health facilities: experience from public health facilities in Northern A. Inedu, F. Oronsaye, C. Imarhiagbe, B. Oyeledun, P. Jwanle, E. Medina, A. Olaitan, B. Uguge, G. Agada TUPED785 Factors associated with disclosure of HIV status following testing HIV-positive at mobile HIV counselling and testing units in TUPED795 Early diagnosis of HIV infections and detection of asymptomatic STI in a community-based organization addressed to MSM TUPED786 TUPED787 TUPED788 PED789- D797 TUPED789 T. Mabuto, S. Charalambous, K. Fielding, G. Churchyard, M. Hlongwane, G. Kubeka, C. Hoffmann Preliminary findings from a care facilitation approach to accelerate entry into care after HIV diagnosis from mobile HIV counselling and testing units in South Africa T. Mabuto, S. Charalambous, K. Fielding, G. Churchyard, M. Nathane-Taulela, C. Hoffmann TB/HIV Care Association's model to increase linkage to care for sex workers: a peer linked mobile service with point of care CD4 testing and STI syndromic management H. Hausler, A. Lambert, H. Mhlope, M. Greeves, W. Joyce, R. Ogle Delays in antiretroviral therapy initiation among HIV-positive individuals: results of a community-based positive living with HIV (POLH) study in Kathmandu, Nepal K.C. Poudel, D.R. Buchanan, K. Poudel- Tandukar Engagement of community in service delivery Enhancing community engagement through involvement of community members in delivery of antiretroviral drugs (ARV) to fellow community members: TASO Rukungiri experience B. Kizito Joseph TUPED796 TUPED797 PED798- D802 TUPED798 TUPED799 P. Coll, A. Leon, F. Garcia, A. Carrillo, E. Fernandez, I. Bravo, J. Saz, M. Meulbroek, F. Pujol, V. Gonzalez, J. Casabona, L. Ferrer, J.L. Blanco, M. Piñol, F. Garcia-Cuyas, G. Sirera, A. Chamorro, B. Revollo, J.M. Gatell, B. Clotet, C. Brander How can involving women living with HIV strengthen the evidence base of our policies and programmes? A methodological analysis A. Welbourn, L. Orza, E. Tremlett, S. Dilmitis, J. Stevenson, C. Kenkem, E. Bell, E.T. Crone, T. Atsbeha, N. Damji, E. Bass, N. Aidarus, K. Fisher Engaging frontline community health workers to provide oral rapid HIV testing to pregnant women in rural India S. Mehra, A. Sarkar, G. Mburu, P. Sharma, J. Behara, S.K. Mishra India Operational challenges in implementing test and treat strategies Feasibility of supervised self-testing using an oral fluid-based HIV rapid testing method among pregnant women in rural India A. Sarkar, G. Mburu, J. Behara, P. Sharma, S.K. Mishra, S. Mehra India Increasing ART retention in Cote d'ivoire through active monitoring and follow-up B.C.J. Diby, K.M. N'goran, N.J.P. N'da, J. Essombo, A. Angel, S. Howard, A. Kouamé Cote d'ivoire TUPED790 TUPED791 Bringing community to cure L. Sylla, M. Louella, E. Seelbach, T. Andrus Implementation of community-based adherence clubs for stable antiretroviral therapy patients A. Grimsrud, J. Sharp, C. Kalombo, L.-G. Bekker, L. Myer TUPED800 Effects of a cognitive-behavioral intervention on condom use and serostatus disclosure in Mexicans living with HIV N.P. Caballero Suárez, E. Rodríguez Estrada, M.C. Iglesias Chiesa, J.M. Menez Díaz, A. Riveros Rosas, G. Reyes Terán Mexico 15 / 17

16 TUPED801 TUPED802 PED803- D825 TUPED803 TUPED804 TUPED805 TUPED806 TUPED807 TUPED808 Using the new ART guidelines to overcome the challenges of paediatric and adolescent ART enrollment in resourcelimited settings: The AIDS Support Organization (TASO) Gulu experience P. Ijotre Peer-provided HIV counselling and testing for key populations in Cambodia: lessons learnt and implications for service delivery T. Sovannary, Y. Siyan, J. Willem van Wijngaarden, M. Srey, G. Mburu Integration of HIV services with other health programmes Integration and utilization of family planning services in a HIV clinic in Nairobi, Kenya E. Njuguna, S. Ilovi, K. Mutai, P. Njoroge, P. Muiruri, J. Kinuthia Kenya Missed opportunities to reduce the risk of cardiovascular disease amongst people living with HIV: high prevalence of untreated cardiovascular disease risk factors at an HIV clinic in M. Rabkin, A. Mutiti, C. Chung, Y. Zhang, Y. Wei, W. El-Sadr Caries experience in HIV-infected, HIVperinatally exposed but uninfected and HIV unexposed, uninfected n children: a comparative study M. Coker, S. El-Kamary, P. Akhigbe, O. Obuekwe, E. Mongodin, M. Charurat, W. Blattner An unannounced standardized patient actor assessment of STI services in public health facilities in P. Kohler, S. Jed, E. Pillay, G. Mema, S. Galagan, J. DeKadt, J. Dombrowski, M. Golden, K. Tapia, E. Naidoo, K. Holmes, E. Marumo Does the patient experience of healthcare change following the implementation of the integration of HIV care into primary health care clinics? Perspectives from patient surveys in Free State A. Rawat, K.E. Uebel, D. Moore, L. Cingl, J. Spiegel, A. Yassi Who doesn't disclose their HIV-positive status? Patterns of disclosure and factors associated with not disclosing to a spouse or primary sexual partner among TB-HIV patients initiating antiretroviral therapy in Lesotho TUPED810 TUPED811 TUPED812 TUPED813 TUPED814 TUPED815 TUPED816 TUPED817 Estimating the need for integrated management of hypertension and diabetes mellitus in HIV patients, Zomba District, Malawi O. Divala, S. Sodhi, N. Kayange, M. Nyirenda, Z. Ismail, M. Joshua, G.S. Chinomba, T. Beyene, A. Kwekwesa, H. Akello, J. Bourgeois, G. Sankhulani, A. Matengeni, G. Mateyu, A. Chan, R. Bedell, T.J. Allain, J. Mallewa, J.J. van Oosterhout Malawi Lipid abnormalities in urban and rural patients on ART in Zomba district O. Divala, S. Sodhi, N. Kayange, M. Nyirenda, Z. Ismail, M. Joshua, G.S. Chinomba, T. Beyene, A. Kwekwesa, H. Akello, J. Bourgeois, G. Sankhulani, A. Matengeni, G. Mateyu, A. Chan, T.J. Allain, J. Mallewa, J.J. van Oosterhout Malawi The impact of integrating HIV and sexual reproductive health services on health and healthcare-seeking behavior of female entertainment workers in Cambodia S. Yi, P. Chhoun, S. Suong, K. Thin, K. Tith, S. Tuot Cambodia A cost-finding study of cervical cancer screening methods integrated into HIV care in Nairobi, Kenya E. Vodicka, J.B. Babigumira, M. Mann, R.J. Kosgei, F. Lee, N. Mugo, T. Okech, S. Sakr, L.P. Garrison, Jr., M.H. Chung Integrating HIV care and treatment services within a methadone clinic in Dar es Salaam, Tanzania: a formative research study H. Saleem, D. Mushi, J. Mbwambo, O. Chang, B.H. Lambdin Early exits from the opioid substitution treatment (OST) in Ukraine: reasons and possible explanation A. Mazhnaya, A. Shost, S. Filippovych, Z. Islam, F.L. Altice Ukraine Accelerated HIV/TB service integration into primary care clinics and programmatic outcomes in rural Swaziland B. Kerschberger, I. Zabsonre, W. Sikhondze, S. Mazibuko, L. Rusike-Pasipamire, A.H. Bakri, S.M. Kabore, I. Ciglenecki Swaziland Baseline assessment on FP service utilization among eligible HIV-positive women in Amhara, Tigray, Oromia, SNNPR and Addis Ababa TUPED809 E. Hayes-Larson, S. Saito, Y. Hirsch- Moverman, L.B. Maama, K. Frederix, B. Pitt, A.A. Howard Incorporating non-communicable disease screening into community-based HIV counselling and testing in Cape Town, M. van Niekerk, H. Draper, S.-A. Meehan TUPED818 TUPED819 N. Barega Ethiopia The favorable value of targeting an alcohol intervention to persons living with HIV/AIDS in Kenya J. Kessler, K. Ruggles, A. Patel, K. Nucifora, L. Li, S. Braithwaite Parents' views and acceptability of early infant male circumcision (EIMC) integrated into maternal child health (MCH) services in Iringa, Tanzania M. Amuri, G. Msemo, J. Lija, M. Plotkin, A. Christensen, R. Lemwyi, D. Boyee, A. Hellar, E. Mlanga, E. Njeuhmeli, H. Mahler Tanzania, United Republic of 16 / 17

17 TUPED820 Can male partners play a role in cervical cancer screening? The knowledge and attitudes of HIV-positive men towards cervical cancer screening in Kenya TUPED830 Community-owned electronic repository: improving data access and uptake to develop evidence-informed policies and programs TUPED821 F. Lee, P. Masitsa, T.K.H. Constant, M.H. Stilwell, N. Yatich, S.R. Sakr, N.R. Mugo, M.H. Chung Patient preference and willingness-to-pay for standalone, integrative and satellite models of dispensing methadone for the treatment of opioid dependence in Vietnam TUPED831 Y. Paul, M. de Bruin, S. Mcleish, M. Fitzgerald, K. Morrison Jamaica Overcoming barriers to opening supervised injection services in the United States L. Thomas B.X. Tran, V.M. Nong, H.T.T. Phan, C. Latkin PED832- D840 Monitoring and evaluation of prevention TUPED822 Impact of peer nutritional counseling on ART patients food insecurity and nutritional outcomes: a pilot study in Honduras K.P. Derose, M. Felician, B. Han, K. Palar, B. Ramirez, H. Farias, H. Martinez TUPED832 Process evaluation of behavioural change communication materials developed and utilized for HIV prevention by nongovernmental organizations in Oyo State, B. Kazeem Kolawole TUPED823 TUPED824 TUPED825 PED826- D828 TUPED826 Integrating HIV and reproductive health services to increase consistent condom use for HIV prevention: a multicentre, non-randomized trial R. Mutemwa, S. Mayhew, C. Warren, J. Kikuvi, D. Wang, Integra Initiative Group The impact of integrated reproductive health and HIV services on HIV testing uptake: results from a cohort study among family planning clients in Kenya K. Church, G. Ploubidis, I. Birdthistle, J. Mak, K. Tomlin, W. Zhou, C. Warren, S. Mayhew, Integra Initiative What influences successful delivery of integrated HIV and FP/PNC services? Evidence from a non-randomised, longitudinal, evaluation trial in Kenya and Swaziland S. Mayhew, R. Mutemwa, M. Colombini, J. Mak, M. Collumbien, I. Lut, I. Birdthistle, C. Ndwiga, Integra Initiative Integration of HIV services with other development programmes An integrated treatment model for opioid addiction to enhance HIV prevention and treatment in Vietnam C.M. Denis, D.S. Metzger, L. Huang, V. Trias, M. Auriacombe, G. Raguin, S. Mai Thi Hoai, G. Le Truong, J.-P. Daulouede, C.P. O'Brien TUPED833 TUPED835 TUPED836 TUPED838 Preliminary reliability and validity results for measures of intergenerational disjuncture that may reflect pathways between social structural change and HIV outbreaks E. Pouget, M. Sandoval, Y. Jones, G. Nikolopoulos, S. Friedman Improved HIV testing uptake, food security and reduced violence among orphans and vulnerable children in Zambia: the impact of using baseline data to define program scope J. Chapman, M. Ngunga, Z. Chariyeva, J. Simbaya, J. Kamwanga, W. Kaira Households that choose to participate in community savings groups are better off than households that do not: findings from an evaluation in Zambia and implications for programming J. Chapman, R. Mswia, Z. Chariyeva, M. Kanema, M. Ngunga, J. Chege, P. Funjika, J. Kamwanga Utilization of Google Earth to georeference survey data among people who inject drugs: strategic application for HIV research L. Beletsky, A. Vera, T. Gaines, J. Arredondo, D. Werb, A. Bañuelos, T. Rocha, M.L. Rolon, D. Abramovitz, J. Amon, K. Brouwer, S.A. Strathdee TUPED827 Decriminalization and public health on the ground: measuring policing and risk environment for people who inject drugs (PWID) in Tijuana, following the Mexican Nacormenudeo reform J. Arredondo, A. Bañuelos, T. Rocha, G. Rangel, S.A. Strathdee, L. Beletsky TUPED839 Efficiency of facility-based HTC and its determinants: results from the ORPHEA study in Kenya, Rwanda, and Zambia S.G. Sosa-Rubí, S. Bautista-Arredondo, M. Opuni, D. Contreras-Loya, I. Ochoa Moreno, ORPHEA Study Group Mexico TUPED828 Community-led integrated service delivery 'war rooms' game changing the fight against HIV/AIDS and TB: case study of the Operation Sukuma Sakhe model in KwaZulu-Natal, T. Zhuwau, V. Naidu, C. Hugo, F. Ndlovu, S. Mkhize, T. Ngwenya, N.I. Ndlovu TUPED840 Efficiency of VMMC and its determinants: results from the ORPHEA study in Kenya, Rwanda,, and Zambia S. Bautista-Arredondo, S.G. Sosa-Rubí, M. Opuni, D. Contreras-Loya, I. Ochoa Moreno, ORPHEA Study Group Mexico PED830- D831 Translation, incorporation and use of key IR findings into programmes and practice 17 / 17

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

HPTN 073: Black MSM Open-Label PrEP Demonstration Project HPTN 073: Black MSM Open-Label PrEP Demonstration Project Overview HIV Epidemiology in the U.S. Overview of PrEP Overview of HPTN HPTN 061 HPTN 073 ARV Drug Resistance Conclusions Questions and Answers

More information

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

HIV Guidelines. New Strategies.

HIV Guidelines. New Strategies. HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV

More information

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Antiretroviral therapy for HIV infection in infants and children: Towards universal access Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous

More information

The Basics of Drug Resistance:

The Basics of Drug Resistance: CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?

More information

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf

More information

Case Finding for Hepatitis B and Hepatitis C

Case Finding for Hepatitis B and Hepatitis C Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department

More information

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)

More information

Aids Fonds funding for programmes to prevent HIV drug resistance

Aids Fonds funding for programmes to prevent HIV drug resistance funding for programmes to prevent HIV drug resistance Call for proposals July 2012 Page 1 van 10 grants@aidsfonds.nl Documentnumber 20120719/JKA/RAP Universal Access Lifting barriers to universal access

More information

The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART?

The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART? World Health Organization brief on antiretroviral treatment (ART) in HIV and TB prevention. Date: January 2011 This brief is intended as an introduction for WHO staff to the HIV and TB preventive benefit

More information

Paediatric HIV Drug Resistance in African Settings

Paediatric HIV Drug Resistance in African Settings Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Will a Pill a Day Keep HIV Away?

Will a Pill a Day Keep HIV Away? Will a Pill a Day Keep HIV Away? Sybil Hosek, PhD Department Of Psychiatry Stroger Hospital Of Cook County YES! BUT ONLY IF YOU TAKE IT What is PrEP? PrEP stands for Pre-Exposure Prophylaxis Prophylaxis

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care Anna Satcher Johnson, MPH Symposium on Measuring the HIV Care Continuum Center for AIDS Research University of Washington

More information

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013 Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013 On July 16, 2012, the Food and Drug Administration (FDA) approved

More information

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...

More information

Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board

Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board The growing crisis of HIV/HCV coinfection It is estimated that 4-5 million people living with HIV (PLHIV)

More information

PRIOR AUTHORIZATION POLICY

PRIOR AUTHORIZATION POLICY PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus

More information

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers

Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers James Wilton Coordinator, Biomedical Science of HIV Prevention

More information

HIV/AIDS Prevention and Care

HIV/AIDS Prevention and Care HIV/AIDS Prevention and Care Nancy S. Padian, PhD, MPH Professor, Obstetrics, Gynecology & Reproductive Sciences Associate Director for Research, Global Health Sciences and AIDS Research Institute: University

More information

Clinical Infectious Diseases Advance Access published September 1, 2015

Clinical Infectious Diseases Advance Access published September 1, 2015 Clinical Infectious Diseases Advance Access published September 1, 2015 1 No New HIV Infections with Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting Jonathan E. Volk 1, Julia

More information

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating

More information

EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN

EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN JUNE 2014 INTRODUCTION Approximately 3.2 million individuals in the United States are infected with chronic hepatitis

More information

The Botswana Combination Prevention Project (BCPP)

The Botswana Combination Prevention Project (BCPP) The Botswana Combination Prevention Project (BCPP) The Next Phase of HIV Prevention in Botswana A collaboration between MoH CDC-Botswana, HSPH-BHP Presenter: M.J. Makhema NAC 4 th September 2012 Mashi

More information

HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE

HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE HARM REDUCTION FOR PEOPLE WHO INJECT DRUGS INFORMATION NOTE Introduction The Global Fund supports evidence-based interventions that aim to ensure access to HIV prevention, treatment, care and support for

More information

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School

More information

Pre-exposure prophylaxis (PrEP)

Pre-exposure prophylaxis (PrEP) FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.

More information

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. HIV & AIDS What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease. What does HIV stand for? Human Immunodeficiency Virus Where did HIV

More information

Tuberculosis OUR MISSION THE OPPORTUNITY

Tuberculosis OUR MISSION THE OPPORTUNITY Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is

More information

Viral load testing. medical monitoring: viral load testing: 1

Viral load testing. medical monitoring: viral load testing: 1 medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the

More information

Global Under Diagnosis of Viral Hepatitis

Global Under Diagnosis of Viral Hepatitis Global Under Diagnosis of Viral Hepatitis Mel Krajden MD, FRCPC Medical Head, Hepatitis Clinical Prevention Services Associate Medical Director, Public Health Microbiology & Reference Laboratory BC Centre

More information

Frequently Asked Questions (FAQs)

Frequently Asked Questions (FAQs) Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing

More information

HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016

HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016 Daily emtricitabine/tenofovir (Truvada ) is safe and effective for reducing the risk of HIV acquisition in sexually

More information

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

Global Update on HIV Treatment 2013: Results, Impact and Opportunities June 2013 Global Update on HIV Treatment 2013: Results, Impact and Opportunities WHO/UNAIDS/UNICEF v2 Outline Results: Progress towards Global Targets - Antiretroviral treatment - Prevention of mother-to-child

More information

Liver Disease and Therapy of Hepatitis B Virus Infections

Liver Disease and Therapy of Hepatitis B Virus Infections Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

HBV screening and management in HIV-infected children and adolescents

HBV screening and management in HIV-infected children and adolescents HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally

More information

What is PrEP, or Pre-Exposure Prevention?

What is PrEP, or Pre-Exposure Prevention? What is PrEP, or Pre-Exposure Prevention? JULY 2011 What is PrEP? An HIV-negative person would use PrEP by taking certain HIV medicines daily (in either a pill or microbicide) to help him or her prevent

More information

Briefing Note: Hepatitis B & Hepatitis C. Summary:

Briefing Note: Hepatitis B & Hepatitis C. Summary: Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and

More information

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Molecular Diagnosis of Hepatitis B and Hepatitis D infections Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication

More information

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive

More information

In Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs.

In Tanzania, ARVs were introduced free-of-charge by the government in 2004 and, by July 2008, almost 170,000 people were receiving the drugs. ANTIRETROVIRAL TREATMENT What is ART and ARV? ART is a short form for Antiretroviral Therapy (or Treatment). Antiretroviral therapy is a treatment consisting of a combination of drugs which work against

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

Positive impact of HCV treatment initiation on health outcomes in injecting drug users

Positive impact of HCV treatment initiation on health outcomes in injecting drug users Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction

More information

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment

More information

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What

More information

HIV Drug resistanceimplications

HIV Drug resistanceimplications HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:

More information

Consolidated guidelines on the use of antiretroviral drugs for treating

Consolidated guidelines on the use of antiretroviral drugs for treating TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO

More information

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

UNAIDS 2013 AIDS by the numbers

UNAIDS 2013 AIDS by the numbers UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since

More information

Aim of Presentation. The Role of the Nurse in HIV Care. Global Epidemic 7/24/09

Aim of Presentation. The Role of the Nurse in HIV Care. Global Epidemic 7/24/09 Aim of Presentation The Role of the Nurse in HIV Care Eileen Nixon HIV Nurse Consultant Brighton and Sussex University Hospitals Overview of key issues that affect people with HIV Identify the role of

More information

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

More information

EACS 2013. Dominique Braun Universitätsspital Zürich

EACS 2013. Dominique Braun Universitätsspital Zürich EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir

More information

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of

More information

Reference: NHS England B06/P/a

Reference: NHS England B06/P/a Clinical Commissioning Policy: Dolutegravir for treatment of HIV- 1 in adults and adolescents Reference: NHS England B06/P/a 1 NHS England Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1

More information

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening

More information

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,

More information

Hepatitis C Vaccines: Are we making progress?

Hepatitis C Vaccines: Are we making progress? Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify

More information

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1: Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture

More information

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL) PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).

Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data). HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and

More information

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:

More information

HEPATITIS COINFECTIONS

HEPATITIS COINFECTIONS HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)

More information

HIV DRUG RESISTANCE EARLY WARNING INDICATORS

HIV DRUG RESISTANCE EARLY WARNING INDICATORS HIV DRUG RESISTANCE EARLY WARNING INDICATORS World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update ACKNOWLEDGEMENTS The preparation

More information

Antiretroviral Drugs in the Treatment and Prevention of HIV Infection

Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev, MD Uses of Antiretroviral Agents Treatment of chronic HIV infection Prevention of mother-to-child transmission [PMTCT]

More information

Prevention of Mother to Child Transmission (MTCT) of HIV

Prevention of Mother to Child Transmission (MTCT) of HIV Prevention of Mother to Child Transmission (MTCT) of HIV Tim Farley Department of Reproductive Health and Research World Health Organization Geneva 17 September 2001 Postgraduate Course in Reproductive

More information

Global Health Research Internship 2016 in Boston

Global Health Research Internship 2016 in Boston 801 Massachusetts Ave, Crosstown 2079 Boston, MA 02118-2335 Tel: 617-414-6933 E-mail: Karsten.Lunze@post.harvard.edu Karsten Lunze, MD, MPH, DrPH, FACPM, FAAP Research Assistant Professor of Medicine Global

More information

July 3, 2015. III. VA policy:

July 3, 2015. III. VA policy: Antiretroviral Postexposure Prophylaxis After Sexual, Injection- Drug Use, or Other Nonoccupational Exposure to HIV (nonoccupational post- exposure prophylaxis [npep]) VA Greater Los Angeles Healthcare

More information

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0 Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharan

More information

New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head

New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head New Approaches to a Major Public-Health Problem Infectious Diseases Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head Overview The Burden Of Infectious Disease Is Large And May

More information

HEPATITIS C AND HIV: A GROWING THREAT TO UNIVERSAL ACCESS

HEPATITIS C AND HIV: A GROWING THREAT TO UNIVERSAL ACCESS Introduction In 2005, G8 leaders promised that by 2010 Universal Access to HIV prevention, treatment, care and support would be widely available. Since then, much has been accomplished and over 2 million

More information

NOTIFIABLE. Infectious Disease Assessment for Migrants 2015 - 27 - RECOMMENDATIONS. Offer test (HBsAg and anti-hbc) to: Vaccinate:

NOTIFIABLE. Infectious Disease Assessment for Migrants 2015 - 27 - RECOMMENDATIONS. Offer test (HBsAg and anti-hbc) to: Vaccinate: 5.2 Hepatitis B NOTIFIABLE RECOMMENDATIONS Offer test (HBsAg and anti-hbc) to: = All new migrants originating from countries with a HBsAg prevalence of 2% = Household and sexual of identified acute or

More information

Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults

Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Reference: NHS England B06/P/x 1 Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults

More information

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n

More information

Aktuell HIV-forskning 2014-05-06

Aktuell HIV-forskning 2014-05-06 Aktuell HIV-forskning 2014-05-06 Alexey Kashpersky Aktuell HIV-forskning Bot Smittsamhet Nya läkemedel HIV och åldrande Etc HPTN 052 Prevention Conclusion Early ART that suppresses viral replication led

More information

50 years THE GAP REPORT 2014

50 years THE GAP REPORT 2014 THE GAP REPORT 2014 People aged 50 years and older The ageing of the world s population is one of the most significant demographic trends of this era, and there are a growing number of people aged 50 and

More information

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission

More information

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen

More information

Goals of Therapy. Treatment Options for Hepatitis C. Patterns of Response. Progress in Hepatitis C Therapy

Goals of Therapy. Treatment Options for Hepatitis C. Patterns of Response. Progress in Hepatitis C Therapy Treatment Options for Hepatitis C Helen S. Te, M.D. Center for Liver Diseases University of Chicago Hospitals Chicago, Illinois Primary: To eliminate the virus Goals of Therapy Secondary: To decrease inflammation

More information

Hepatitis at a national level: government perspectives

Hepatitis at a national level: government perspectives Hepatitis at a national level: government perspectives Presenter: Dr Shin Young-Soo Regional Director WHO Western Pacific Panel The Honourable Dr. David Sergeenko Minister of Health, Labour and Social

More information

Stigma and discrimination as barriers to achievement of global PMTCT and maternal health goals

Stigma and discrimination as barriers to achievement of global PMTCT and maternal health goals Stigma and discrimination as barriers to achievement of global PMTCT and maternal health goals Janet M. Turan University of Alabama at Birmingham Laura Nyblade USAID-funded Health Policy Project MHTF Maternal

More information

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000

More information

Routine HIV Monitoring

Routine HIV Monitoring Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral

More information

The question and answer session is not available after the live webinar.

The question and answer session is not available after the live webinar. 1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments

More information

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND EPIDEMIOLOGY OF HEPATITIS B IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 11 References 12 Epidemiology of Hepatitis

More information

Estimates of New HIV Infections in the United States

Estimates of New HIV Infections in the United States Estimates of New HIV Infections in the United States Accurately tracking the HIV epidemic is essential to the nation s HIV prevention efforts. Yet monitoring trends in new HIV infections has historically

More information

Session 4: The Drug Management Cycle: Selection. David Peters

Session 4: The Drug Management Cycle: Selection. David Peters This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.

More information

Collaborative TB and HIV Services for Drug Users. Christian Gunneberg M.O. WHO

Collaborative TB and HIV Services for Drug Users. Christian Gunneberg M.O. WHO Collaborative TB and HIV Services for Drug Users Christian Gunneberg M.O. WHO What I will address The problems of HIV/TB and Drug use. The policy guide. What next. Drug use and HIV Drug users are a large

More information

Placing Nation on the Path Toward the Elimination of Hepatitis C

Placing Nation on the Path Toward the Elimination of Hepatitis C Placing Nation on the Path Toward the Elimination of Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for

More information

Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B

Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC

More information

Evidence-Based Practice for Public Health Identified Knowledge Domains of Public Health

Evidence-Based Practice for Public Health Identified Knowledge Domains of Public Health 1 Biostatistics Statistical Methods & Theory Evidence-Based Practice for Public Health Identified Knowledge Domains of Public Health General Public Health Epidemiology Risk Assessment Population-Based

More information

September 17, 2010. Dear Secretary Sebelius:

September 17, 2010. Dear Secretary Sebelius: September 17, 2010 Secretary Kathleen Sebelius Department of Health and Human Services Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201 RE: Comments on OCIIO- 9992- IFC, Interim

More information